The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review  by Oliansky, Denise M. et al.
REVIEWFrom the
versit
ter, N
Minn
Hosp
sity, C
Island
Omah
Unive
Cente
Financial d
Correspon
Park
14263
Received M
 2011 Am
1083-8791
doi:10.101
20The Role of Cytotoxic Therapy with Hematopoietic
Stem Cell Transplantation in the Treatment
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Denise M. Oliansky,1 Myron Czuczman,1 Richard I. Fisher,2 Frank D. Irwin,3
Hillard M. Lazarus,4 James Omel,5 Julie Vose,6 Steven N. Wolff,7
Roy B. Jones,8 Philip L. McCarthy Jr.,1 Theresa Hahn1Clinical research published since the 2001 evidence-based review on the role of hematopoietic stem cell
transplantation (SCT) in the treatment of diffuse large B cell lymphoma (DLBCL) in adults is presented
and critically evaluated in this update. Treatment recommendations that remain unchanged from the original
review include: (1) autologous SCT as salvage therapy is recommended for patients with chemosensitive
relapsed DLBCL; and (2) autologous SCT is not recommended for patients who achieve a partial response
to an abbreviated induction regimen. New treatment recommendations based on new published data in-
clude: (1) autologous SCT as first-line therapy is not recommended for any IPI group; (2) planned tandem
or multiple sequential autologous SCT is not recommended; (3) peripheral blood is the standard stem
cell source for autologous SCT; (4) age is not a contraindication for autologous SCT, although outcomes
in older adults are not as good as in younger adults. There are insufficient data to make recommendations
on the routine use of rituximab maintenance after autologous SCT, autologous versus allogeneic SCT, fewer
versus more cycles of induction therapy prior to autologous SCT, or the use of reduced intensity versus
myeloablative conditioning regimens. Areas of needed research in the treatment of DLBCL with SCT
were identified and are presented in the review.
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6/j.bbmt.2010.07.008tion statements on the effectiveness of autologous and
allogeneic hematopoietic stem cell transplantation
(SCT) for specific diseases. In 2009, the ASBMT
EBR Steering Committee determined that previously
published reviews should be updated regularly at ap-
proximately 5-year intervals. This constitutes the first
EBR in the series to be updated.UPDATEOFTHE 2001DIFFUSE LARGEBCELL
LYMPHOMA (DLBCL) EVIDENCE-BASED
REVIEW
It is important to note that the study inclusion cri-
teria, the systems for grading the quality and strength
of the evidence and the strength of the treatment rec-
ommendations, and the format of the reviews have
changed considerably since the original DLBCL
EBR was published. The DLBCL update adheres to
the methodology and grading systems presented in
Appendix A (online only). In the original DLBCL
EBR [1], each article was summarized in detail in the
Table 1. Summary of Updated Treatment Recommendations for Diffuse Large B Cell Lymphoma
Indication for SCT Original versus New Rec
Tx Rec
Grade*
Highest Level
of Evidence† Ref. No.‡
Treatment Recommendation
Comments
Autologous SCT versus
nontransplantation
as first-line therapy
New recommendation based on
new data published since the
original review
A 1++ [2-7, 9-11] (Table 2) Autologous SCTas first-line therapy
is not recommended for any IPI
group at this time.
None of the published studies
included rituximab in their
protocols. Ongoing studies,
which include rituximab, may
change this recommendation.
Autologous SCT versus
nontransplantation
as therapy for patients who
achieve a partial response
to 3 cycles of induction
Original recommendation is
unchanged with no new data
published since the original
review
A 1+ [18] (Table 3) Autologous SCT is not
recommended for patients who
achieve a partial response to an
abbreviated (3 cycles) induction
regimen.
Autologous SCT versus
nontransplantation
as salvage therapy
Original recommendation is
unchanged with no new data
published since the original
review
A 1+ [19] (Table 4) Autologous SCT provides
a significant survival benefit and is
recommended as part of salvage
therapy for patients with
chemosensitive relapsed DLBCL.
TRANSPLANTATION TECHNIQUES
Autologous SCT as salvage
therapy for patients
aged >60 years
New recommendation based on
new data published since the
original review
B 2+ [20-22] (Table 5) Older age (>60 years), in and of
itself, is not a contraindication for
autologous SCT as long as other
SCTeligibility criteria aremet. No
upper age limit has been defined.
However, outcomes (TRM,
relapse, survival) in older adults
are not as good as in younger
adults.
Autologous versus ablative
allogeneic SCT
No treatment recommendation
based on new data published
since the original review
2++ [23] (Table 6) Overall survival outcomes are
equivalent for autologous and
allogeneic SCT; neither option is
recommended over the other.
Autologous and allogeneic SCT
have competing risks with regard
to relapse and TRM. Comparison
of these two techniques is biased
by different patient selection
criteria.
Bone marrow versus
peripheral blood as
the stem cell source
for autologous SCT
New recommendation
based on new data published
since the original review
A 1++ [25] (Table 7) Autologous PBSCT provides no
survival benefit or improved
tumor control compared to
autologous BMT. However,
PBSCT is safer and easier to use
with faster engraftment and
lower rate of deaths because of
infection, hence peripheral blood
is the standard for stem cell
source. Of note, 98% of recent
autologous SCTs use peripheral
blood as the stem cell source.§
Rituximab as maintenance
therapy after
autologous SCT
No treatment recommendation
based on new data published
since the original review
1+ [26] (Table 7) There are insufficient data to
recommend routine post-
autologous SCT maintenance
with rituximab outside of
a clinical trial. One randomized
study with short follow-up
reported a nonsignificant
difference in EFS with rituximab
as maintenance after autologous
SCT.
Fewer versus more cycles of
induction therapy prior to
first-line autologous SCT
No treatment recommendation
based on new data published
since the original review
2++ [27] (Table 7) Based on one study, there are
insufficient data to make
a treatment recommendation
regarding fewer versus more
cycles of induction therapy prior
to first-line autologous SCT.
Multiple or tandem
autologous SCT
New recommendation based on
new data published since
the original review
B 2+ [44-47] (Appendix C) Based on evidence from phase II
trials, planned tandem or multiple
(Continued )
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Table 1. (Continued )
Indication for SCT Original versus New Rec
Tx Rec
Grade*
Highest Level
of Evidence† Ref. No.‡
Treatment Recommendation
Comments
sequential autologous SCTs are
not recommended.
Reduced intensity versus
myeloablative
conditioning
for allogeneic SCT
No treatment recommendation
based on new data published
since the original review
2+ [28] (Table 8) Based on one study and expert
opinion, RIC appears to be an
acceptable alternative approach
for selected patients who cannot
tolerate a myeloablative regimen.
However, longer follow-up is
needed to clarify the competing
risks of relapse and chronic
GVHD and their impact on
overall survival and quality of life.
Comparison of these regimen
intensities are biased by patient
selection criteria which have
changed over time.
BMT indicates bone marrow transplantation; DLBCL, diffuse large B cell lymphoma; EFS, event-free survival; GVHD, graft-versus-host disease; IPI,
International Prognostic Index; PBSCT, peripheral blood stem cell transplantation; SCT, stem cell transplantation; TRM, treatment-related mortality.
*Definitions: Grade of Recommendation (Appendix A, Table 2, online only): (A) At least one meta-analysis, systematic review, or randomized
controlled trial (RCT) rated as 1++, and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting
principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results; (B) A body of evidence
including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence
from studies rated as 1++ or 1+; (C) A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating
overall consistency of results; or extrapolated evidence from studies rated as 2++; (D) Evidence level 3 or 4; or extrapolated evidence from studies rated
as 2+.
†Definitions: Levels of Evidence (Appendix A, Table 1, online only): 1++, High-quality meta-analyses, systematic reviews of randomized controlled
trials (RCTs), or RCTs with a very low risk of bias; 1+ Well-conducted meta analyses, systematic reviews of RCTs, or RCTs with a low risk of bias; 12
Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; 2++, High-quality systematic reviews of case-control or cohort studies; or
high-quality case-control or cohort studieswith avery low riskof confounding, bias, orchance and a high probability that the relationship is causal; 2+Well-
conducted case control or cohort studies with a low risk of confounding, bias, or chance, and a moderate probability that the relationship is causal; 22
Case-control or cohort studies with a high risk of confounding, bias, or chance, and a significant risk that the relationship is not causal; 3 Nonanalytic
studies (eg, case reports, case series); 4 Expert opinion.
‡The references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence de-
scribed in each section of the review.
§Based on CIBMTR data from 2002-2006.
22 Biol Blood Marrow Transplant 17:20-47, 2011D. M. Oliansky et al.text, accompanied by summary tables comparing pa-
tient outcomes. To streamline this update, a concise
summary of each section will be provided in the text,
whereas descriptions of the study design, patient pop-
ulation, and clinical outcomes of each article will be
presented in detailed summary tables.TREATMENT RECOMMENDATIONS
In this DLBCL update, Table 1 contains the sum-
mary of consensus treatment recommendations made
by the expert panel based on the summarized evidence.
The consensus process is detailed in Appendix A (online
only) and involves a teleconference during which panel-
ists critically discuss the evidence for each section of the
review and develop initial treatment recommendations
according to the categories in Appendix A, Table 2.
Table 1 presents new treatment recommendations
based on the DLBCL evidence published since 2000.
In addition, the recommendations from the original
EBR are incorporated into the table when applicable,
regraded according to the schema in Appendix A,
Table 2, and notated as to whether new evidencestrengthens, weakens, or does not change the original
recommendation.AUTOLOGOUS SCT VERSUS
NONTRANSPLANTATION THERAPY
Autologous SCT versus Nontransplantation
as First-line Therapy
Published since the original EBR are two meta-
analyses and nine prospective, multicenter, randomized
studies comparing the efficacy of full-course chemother-
apy versus abbreviated (typically\4 cycles) and/or high-
dose sequential chemotherapy regimens followed by
autologous SCT as first-line treatment for patients with
de novo DLBCL. Table 2 presents a detailed summary
of the study designs, patient populations, and outcomes
from this new evidence. Rituximab was not part of the
protocol in any of these studies. Three Phase III studies
from the original DLBCL EBR that compared autolo-
gous SCT versus nontransplantation therapy, and that
met current inclusion criteria (full-length, peer-
reviewedarticles), are alsopresented inTable2according
to the new format and grading criteria.
Table 2. Autologous SCT versus Nontransplantation as First-Line Therapy for DLBCL
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
UPDATE DATA (POST-2000 STUDIES)
META-ANALYSES OF AUTOLOGOUS SCT VERSUS CHEMO AS FIRST-LINE THERAPY
[2] Chemo Auto SCT Chemo Auto SCT Chemo Auto SCT
Greb 2007
1++ Full or sequential therapy
with variety of combination
chemo regimens
Full induction, Abbreviated,
or Sequential high-dose
therapies
Diagnoses
de novo
aggressive NHL 100% 100%
Relative risk to
achieve CR
RR 1.11 favoring Auto SCT
(CI 1.04-1.18)
Meta-analysis
Search from 1990-1/2005
15 Randomized trials
11 Full-text; 4 Abstracts
Summary data
Total n 5 2728
BM, PBSC, or both
for Auto SCT
TRM
(14 studies,
N 5 2555)
4.3%
(55/1274)
5.7%
(73/1281)
>.05
HR for EFS HR 0.92 (CI 0.80-1.05)
(12 studies,
n 5 1795)
No significant difference in EFS
between Tx groups
HR for OS HR 1.05 (CI 0.92-1.19)
(14 studies, n 5 2444) No significant difference in OS
between Tx groups
OS Subgroup Analysis by aaIPI (12 studies)
Good risk HR 1.46 (CI 1.02-2.09)
Impaired OS for SCT pts, P 5 .032
Poor risk HR 0.95 (CI 0.81-1.11)
No difference in OS by Tx
[3] Chemo Auto SCT Chemo Auto SCT Chemo Auto SCT
Strehl 2003 Mortality 36.4%
(406/1115)
36.9%
(411/1113)
.80
1++ Full or sequential
therapy with variety of
combination chemo
regimens
Full induction,
Abbreviated, or
Sequential high-dose
therapies
BM, PBSC, or both
for Auto SCT
Diagnoses
de novo intermediate
or high risk
aggressive NHL 100% 100%
Heterogeneity
among studies
c2 5 33 .0003
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
Meta-analysis Mortality based on Induction Intensity:
Search thru March, 2003
11 Randomized trials
9 Full-text; 2 Abstracts
Summary data
Total n 5 2228
Full course
(2 studies,
n 5 655)
33.2%
(111/334)
31.7%
(105/331)
.70
Shortened 35.7% 39.9% .12
(n 5 1341) (238/667) 269/674)
HDS 47.4% 30.1% .01
(2 studies, n 5 228) (54/114) (33/108)
Mortality based on IPI (7 studies, n 5 1280):
I-H + H Risk 45.6% 41.3% .40
(273/651) (287/629)
I-H + H Risk 49.7% 35.2% .01
+ Full course Induction (2
studies, n 5 306)
(73/147) (56/159)
I-H + H Risk 44.3% 44.7% .80
+ Shortened Induction (4
studies, n 5 850)
(185/418) (193/432)
STANDARD CHEMOVERSUS ABBREVIATED CHEMO + AUTOLOGOUS SCT
[4] HDT +
Auto PBSCT
HDT +
Auto PBSCT
(5 y, not
stated)
HDT +
Auto PBSCTGisselbrecht 2002 ACVBP ACVBP ACVBP
Diagnoses (181) (189)
1++ 4 ACVBP + GF 1 CEOP + MTX de novo (ITT)
2 MTX 2 ECVBP + GF aggressive NHL 100% 100%
1993-1995 4 VP-16 + Ifo Completed
GELA LNH93-3 2 Ara-C BEAM Hist. Subtypes .07 Assigned Tx Not stated 74%
Multictr (18) DLBCL 62.5% 60%
Prospective Auto PBSC Nonanaplastic Overall CR 64% 63%
Randomized n 5 370 T cell 10.5% 19%
Anaplastic T cell 10.5% 5% TRM Not stated 1%
Med Age (range) Lymphoblastic 4% 3%
46 y (15-60) Burkitt 0.5% 3% 5-year EFS 51 ± 8 39 ± 8 .01
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
Diffuse, aggress,
unclassifiable
12% 10% 5-year OS 60 ± 8 46 ± 8 .007
B symptoms 67% 73% .20 For aaIPI $3
5-year EFS 47% 40% .50
BM Involvement 26% 32% .20 5-year OS 52% 48% .90
Bulky Disease 48% 44% .40
Risk Factors
age >40 y 62% 67% .30
aaIPI $3 35.5% 34% .40
Stage $III 95% 94% .50
LDH $Normal 91% 94% .17
>1 Ex-nodal sites 54% 72% .0004
PS $1 47% 45% .40
[5] Kaiser 2002 CHOEP CHOEP + Auto SCT CHOEP CHOEP +
Auto SCT
Not
stated
(3.8 y, Not stated) CHOEP CHOEP + Auto SCT
1++ 5 CHOEP 3 CHOEP Diagnoses (154) (158)
+ GF de novo (ITT)
aggressive NHL 100% 100%
1990-1997 (± RT for bulky dis.) Completed
German HG NHL BEAM Hist. Subtypes Assigned Tx 89% 65%
Multictr (71) DLBCL 61% 58%
Prospective Auto PBSC or BM PMBL 16% 9% Overall CR 62.9% 69.9%
Randomized n 5 312 Anaplastic LCL 10% 9%
(± RT for bulky dis.) Lymphoblastic or TRM 2.6% total†
Med Age (range) Burkitt 5% 11%
46 y (19-60) Peripheral T cell 4% 3% 3-year EFS 49% 59% .22
Other 4% 10%
3-year OS 63% 62% .68
Bulky Disease 58% 61%
Secondary
Risk Factors Disease 2.5% 1%
age >50 y 37% 35%
IPI $3 75% 73%
Stage $III 63% 66%
LDH >400 U/L 50% 50%
PS > 2 13% 16%
[6] Kluin-Nelemans 2001 Chemo HDT + Auto BMT Chemo HDT + Auto
BMT
Not
stated
(4.4 y, 3.9-4.8 y) Chemo HDT + Auto BMT
1++ 8 CHVmP/BV 6 CHVmP/BV Diagnoses (96) (98)
+ GF de novo (ITT)
aggressive NHL 100% 100%
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
1990-1998 (± RT for bulky dis.) Completed
EORTC Multictr (300+) BEAC Hist. Subtypes Assigned Tx 85% 61%
Prospective DLBCL 58% 50%
Registered n 5 311 Auto BM Anaplastic 12% 18% Overall CR 58% 69%
Randomized n 5 194 PMBL 2% 2%
(± RT for bulky dis.) Marginal B cell 3% 2% NRM 15% 15%
Med Age (range) Mantle cell 3% 1%
Chemo 44 y (16-63) Peripheral T cell 2% 1% 5-year PFS 56% 61% >.05
HDT + Auto 41 y (16-65) Other 3% 2% CI 45%-67% CI 51%-72%
Unclassifiable 12% 20%
Ineligible (included) 5% 4% 5-year OS 77% 68% >.05
CI 67%-86% CI 57%-79%
B symptoms 37% 36%
BM Involvement 11% 15%
Bulky Disease 42% 46%
Risk Factors
age >60 y 2% 3%
aaIPI $3 29% 31%
Stage $III 52% 57%
LDH >Normal 50% 47%
>2 Ex-nodal sites 9% 10%
[7] Martelli 2003 MACOP-B MACOP-B +
Auto PBSCT
MACOP-B MACOP-B +
Auto PBSCT
(2 years, Not stated) MACOP-B MACOP-B + Auto
PBSCT
1++ Diagnoses (75) (75)
12 MACOP-B 8 MACOP-B de novo (ITT)
IG or HG NHL 100% 100%
1994-1999 (± RT for bulky dis.) BEAC Completed
Multictr (18) Hist. Subtypes Assigned Tx 84% 60%
Prospective Auto PBSC DLBCL 81% 70%
Randomized n 5 150 + GF Peripheral T-cell 12% 7% Overall CR 68% 76% >.10
Anaplastic 4% 15% <.05
Med Age (range) (± RT for bulky dis.) LC, unspecified 3% 8% TRM 1% 3%
MACOP-B 45 y (18-60)
MACOP-B + Auto B symptoms 46% 58% 5-year PFS 49% 61% .21
41 y (19-60) CI 29%-43% CI 36%-49%
BM Involvement 17% 16%
5-year OS 65% 64% .95
Bulky Disease 45% 53% CI 40%-53% CI 40%-53%
Risk Factors Secondary
IPI $3 35% 32% Neoplasias 0% 0%
Stage $III 95% 86%
LDH > Normal 91% 85%
PS $2 51% 61%
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
[8] Milpied 2004 CHOP HDT + Auto PBSCT CHOP HDT + Auto
PBSCT
(4 years, Not stated) CHOP HDT + Auto
PBSCT
1+ Diagnoses (99) (98)
8 CHOP 2 CEEP + GF de novo (ITT)
IG or HG NHL 100% 100%
1994-1999 (± RT for bulky dis.) Ara-C + MTX Completed
GOELAMS Multictr (16) BEAM + GF Hist. Subtypes .30 Assigned Tx 72% 85%
Prospective DLBCL 75% 78%
Randomized n 5 197 Auto PBSC Anaplastic 5% 10% Overall CR 62% 81%
Diffuse, unspec. 4% 7%
Med Age (range) (± RT for bulky dis.) T cell lymphoma 16% 5% TRM 1% 3%
CHOP 50 y (20-60)
HDT + Auto 45 y (15-60) BM Involvement 24% 33% .20 5-year EFS 37 ± 5% 55 ± 5% .037
Risk Factors 5-year OS 56 ± 5% 71 ± 5% .076
Age >50 y 44% 32% .07
aaIPI $3 49% 57% .50 For aaIPI < 3
Stage $III 78% 84% .50 5-year EFS 45% 54% .90
LDH >Normal 52% 56% .12 5-year OS 68% 66% .40
>1 Ex-nodal sites 19% 29%
PS $2 19% 10% .11 For aaIPI $ 3
5-year EFS 28 ± 6% 56 ± 7% .003
5-year OS 44 ± 7% 74 ± 6% .001
STANDARD CHEMOVERSUS HIGH DOSE SEQUENTIAL (HDS) THERAPY (± ABBREVIATED CHEMO) + AUTO SCT
[9] Olivieri 2005 VACOP-B HDS + Auto PBSCT VACOP-B HDS +
Auto PBSCT
Not stated (4.4 y, 0.2-8.2 y) VACOP-B HDS + Auto
PBSCT
1++ Diagnoses (106) (117)
12 VACOP-B 8 VACOP-B de novo (ITT)
Y aggressive NHL 100% 100%
1995-2001 (± RT for bulky dis.) Cy + GF Completed
NHLCSG Multictr (18) Y Hist. Subtypes Assigned Tx 100% 68%
Prospective VP-16 DLBCL 83% 74%
Randomized n 5 223 If PR/NR after Y Anaplastic LC 12% 15% Overall CR 76% 73% .06
12 VACOP-B BEAM Other, Inelig. 0% 4%
Med Age (range) Y Y Unclassifiable 4% 7% TRM 1% 4%
VACOP-B 42 y (15-60) Cy + VP-16 Auto PBSC Missing 1% 0%
HDS + Auto 46 y (18-59) + GF, BEAM + 7-year PFS 44.9± 5.1% 40.9 ± 7.7% .70
Auto PBSCT ± RT (± RT for bulky dis.) B symptoms 48% 46%
7-year OS 60 ± 5.4% 57.8 ± 5.2% .50
If Relapse BM Involvement 19% 25%
after CR to Secondary
12 VACOP-B Bulky Disease 37% 39% Neoplasias 2% 2%
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
Y
2 DHAP, BEAM + Risk Factors For aaIPI $3
Auto PBSCT ± RT aaIPI $3 68% 72% 7-year PFS 35.8% 40.7% .50
Stage $III 81% 84% 7-year OS 49.6% 47.8% .60
LDH >Normal 64% 54%
>2 Ex-nodal sites 22% 23%
PS $2 14% 22%
[10] Betticher 2006 CHOP HDS + Auto PBSCT CHOP HDS + Auto
PBSCT
All >.05 (4 y, Not stated) CHOP HDS + Auto
PBSCT
1++ Diagnoses (59) (70)
6-8 CHOP APO or CHOP de novo (ITT)
Y aggressive NHL 100% 100%
1997-2003‡ (± RT for bulky dis.) Cy + GF Completed
MISTRAL Multictr (6) Y Hist. Subtypes Assigned Tx 84% 63%
Prospective VCR + MTX DLBCL 69% 76%
Randomized n 5 129 Y PMBL 15% 17% Overall CR 68% 66%
VP-16 + GF Anaplastic 15% 7%
Med Age (range) Y Unknown 1% 0% TRM 3% 4%
CHOP 46 y (18-61) Mito + Mel + GF
HDS + Auto 49 y (18-61) Y B symptoms 59% 44% 3-year EFS 33% 39% .67
Auto PBSC
BM Involvement 22% 23% 3-year OS 53% 46% .48
(± RT for bulky dis.) CI 39%-67% CI 34%-58%
Bulky Disease 76% 67%
Risk Factors
IPI $3 88% 82%
Stage $III 76% 70%
LDH >Normal 90% 87%
Ex-nodal involvement 27% 21%
PS $2 45% 27%
[11] Vitolo 2005 MegaCEOP HDS + Auto PBSCT Mega
CEOP
HDS + Auto
PBSCT
(6.5 y, Not stated) MegaCEOP HDS + Auto
PBSCT
Diagnoses (66) (60)
1++ 6-8 MegaCEOP 1-2 APO de novo DLCL 100% 100%
+ GF Y (ITT)
1996-2001 Cy + GF Hist. Subtypes
IIL Multictr (14) (± RT for bulky dis.) Y DLBCL 90% 80% Completed
Prospective MTX + VCR PMBL 6% 10% Assigned Tx 92% 83%
Randomized n 5 130 Y Immunoblastic 3% 7%
Eligible n 5 126 VP-16 or DHAP Anaplastic 1% 3% Overall CR 70% 59%
Y
Med Age (range) Mito + Mel B symptoms 55% 70% <.05 TRM 3% 3%
MegaCEOP 43 y (18-60) Y
HDS + Auto 42 y (18-59) Auto PBSC BM Involvement 27% 22% 6-year FFS 48% 45% .56
(Continued )
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
(± RT for bulky dis.) Bulky Disease 42% 60% <.05 6-year OS 63% 49% .06
Risk Factors Secondary
aaIPI $3 80% 87% Neoplasias 0% 3%
Stage $III 82% 74%
LDH $Normal 74% 75% For aaIPI $ 3
>1 Ex-nodal sites 21% 25% OS 58% 48% .12
PS $1 56% 63%
[12] Baldissera 2006 VACOP-B HDS + Auto PBSCT VACOP-B HDS + Auto
PBSCT
(1.9 y, Not stated) VACOP-B HDS + Auto
PBSCT
Diagnoses (27) (29)
12 12 VACOP-B 6 VACOP-B de novo (ITT)
Y aggressive NHL 100% 100%
1998-2003 If PD/NR after 6x Cy + GF Completed
GEMOH Multictr (7) Y Y Hist. Subtypes .32 Assigned Tx 70% 62%
Prospective Transplant Tx VP-16 DLBCL 81% 83%
Randomized n 5 56 Y Other 19% 17% Overall CR 52% 55% .80
BEAM
Med Age (range) As rescue for Y B symptoms 89% 73% .12 TRM 19% 24%
VACOP-B 40 y (17-58) PR/NR after Auto PBSC
HDS + Auto 31 y (18-61) 12 VACOB-B Bulky Disease 48% 55% .60 5-year EFS 47% 30% .50
Y (Salvage chemo
per physician)
DHAP + Risk Factors 5-year OS 47% 40% .80
Cy + VP-16 IPI 5 High Risk 59% 27% .02
+ BEAM + Auto Stage $III 100% 90% .21
LDH >Normal 85% 87% .78
(Salvage chemo per physician) $2 Ex-nodal sites 22% 20% .78
PS $2 45% 31% .58
ORIGINAL DLBCL EBR PHASE III STUDY
SEQUENTIAL CHEMOVERSUS AUTOLOGOUS BMTAFTER CR TO INDUCTION THERAPY
[13] Haioun 2000 Sequential Chemo Auto BMT Sequential
Chemo
Auto BMT All >.05 (8 y, Not stated) Sequential Chemo Auto BMT
(Final analysis of [14, 15]) Diagnoses (111) (125)
1+ MTX MTX de novo poor risk (ITT)
Y aggressive NHL 100% 100%
Ifo + VP-16 CBV Completed
1987-1993 Y Hist. Subtypes Assigned Tx 100% 69%
GELA LNH87-2 L-Asparaginase Auto BM DLBCL 61% 63%
Multictr (35) Y Immunoblastic 13% 11% 8-year DFS 39% 55% .02
Registered n 5 1043 Ara-C Small uncleaved 5% 6% CI 29%-49% CI 46%-64%
(Continued )
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
High risk n 5 451 Follicular 3% 2%
Achieved CR n 5 277 Lymphoblastic 2% 2% 8-year OS 49% 64% .04
Randomized n 5 236 Other 16% 16% CI 39%-59% CI 55%-73%
Med Age (range) BM Involvement 34% 26% Secondary
41 y (16-55) Disease 2% 0%
Bulky Disease 70% 74%
Risk Factors
aaIPI $3 100% 100%
Stage $III 93% 91%
LDH >Normal 92% 86%
$2 Ex-nodal sites 30% 33%
PS $2 44% 42%
ORIGINAL DLBCL EBR PHASE III STUDY
FIRST-LINE VACOP-B VERSUS VACOP-B + AUTOLOGOUS SCT
[16] Santini 1998 VACOP-B VACOP-B + Auto BMT VACOP-B VACOP-B +
Auto BMT
Not stated (3.5 y, Not stated) VACOP-B VACOP-B +
Auto BMT
1+ Diagnoses (61) (63)
12 VACOP-B 12 VACOP-B de novo poor risk
aggressive NHL 100% 100%
1991-1995 (DHAP ± RT for BEAM (ITT)
NHLCSG Multictr (16) salvage) Hist. Subtypes
Prospective Auto BM + GF DLBCL 60% 65% Completed
Randomized n 5 124 ± RT Immunoblastic 20% 21% Assigned Tx 100% 71%
Anaplastic 12% 8%
Med Age (range) (DHAP ± RT for salvage) Unclassifiable 8% 6% Overall CR 75% 73% >.05
VACOP-B 45 y (18-59)
VACOP-B + Auto SCT B symptoms 41% 52% TRM 7% 6%
40 y (16-60)
Bulky Disease 49% 65% 6-year PFS 48% 60% .40
CI 33%-61% CI 48%-72%
Risk Factors
aaIPI $3 59% 54% 6-year OS 65% 65% .50
Stage $III 71% 65% CI 50%-79% CI 53%-77%
LDH >Normal 56% 64%
>2 Ex-nodal sites 25% 24% Secondary
PS $2 15% 19% disease 2% 0%
(Continued )
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Table 2. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
and Pt. Outcomes
Treatment Group
P
Control
Therapy
Transplant
Therapy Disease Characteristic
Control
Group
Transplant
Group P Control (n) Transplant (n)
ORIGINAL DLBCL EBR PHASE III STUDY
FIRST-LINE CHEMO (MACOP-B) VERSUS HDS THERAPY + AUTOLOGOUS SCT
[17] Gianni 1997 MACOP-B HDS + Auto SCT MACOP-B HDS +
Auto SCT
(4.6 y, 1.1-8.6 y) MACOP-B HDS + Auto SCT
1+ Diagnoses (50) (48)
12 MACOP-B ± RT Dox + VCR + Pred DLBCL 100% 100%
1987—Not stated Y
Single Center If Rel/Prog Cy + GF Bulky Disease 70% 76% (ITT)
Prospective during Tx Y
Registered n 5 101 Y VCR + MTX Risk Factors Completed
Randomized n 5 98 HDS therapy Y aaIPI $3 74% 94% Assigned Tx 100% 100%
VP-16 + GF Stage $III 68% 72%
Med Age (range) Y LDH >Normal 74% 78% Overall CR 70% 96% .001
MACOP-B 35 y (17-60) TBI + Mel + GF >2 Ex-nodal sites 70% 78%
HDS + Auto 34 y (18-59) or PS $2 68% 87% .03 TRM 6% 8%
Mito + Mel + GF
7-year EFS 49% 76% .004
(± RT)
Y 7-year OS 55% 81% .09
Auto PBSC or BM CI 36-73% CI 68%-91%
If Rel/Prog during Tx Y
MACOP-B
Secondary disease 2% 2%
aaIPI indicates age-adjusted International Prognostic Index; ACVBP, doxorubicin/cyclophosphamide/vindesine/bleomycin/prednisone; Allo, allogeneic; APO, doxorubicin/ vincristine/prednisone; Ara-C, cytarabine; Auto, autol-
ogous; BEAC, carmustine/etoposide/cyclophosphamide/cytarabine; BEAM, carmustine/etoposide/cytarabine/melphalan; BM, bone marrow; BMT, bone marrow transplantation; CBV, cyclophosphamide/carmustine/etoposide;
CEEP, cyclophosphamide/epirubicin/vindesine/prednisone; CEOP, cyclophosphamide/ epirubicin/vincristine/prednisone; Chemo, chemotherapy; CHOEP, CHOP+Etoposide; CHOP, cyclophosphamide/doxorubicin/vincristine/
prednisone; CHVmP/BV, cyclophosphamide/doxorubicin/teniposide/prednisone/bleomycin/vincrisine; CI, 95% confidence interval; CR, complete remission; CRu, unconfirmed CR; Cy, cyclophosphamide; DFS, disease-free sur-
vival; DHAP, dexamethasone/cytarabine/cisplatin; DLCL, diffuse large cell lymphoma; DLBCL, diffuse large B cell lymphoma; EBR, evidence-based review; ECOG, Eastern Cooperative Oncology Group; ECVBP, epirubicin/cy-
clophosphamide/vindesine/bleomycin/prednisone; EFS, event-free survival; EORTC, European Organization for Research and Treatment of Cancer; Ex-nodal, extranodal; FFS, failure-free survival; G-CSF, granulocyte-colony
stimulating factor; GELA, Groupe d’Etude des Lymphomes de l’Adulte; GEMOH, Grupo de Estudos Multiceˆntricos em Onco-Hematologia; GF, growth factor; GOELAMS, Groupe Ouest-Est des Leuce´mies et des Autres Mal-
adies du Sang; HD, high dose; HDS, high-dose sequential chemotherapy; HDT, high-dose therapy; HG, high grade; Hist., histological; HR, high risk or hazard ratio; IG, intermediate grade; Ifo, ifosfamide; IIL, Intergruppo Italiano
Linfomi; IPI, International Prognostic Index; ITT, intention to treat; LC, large cell; LDH, lactate dehydrogenase; MACOP-B, methotrexate/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin; Mel, melphalan; MIS-
TRAL, Multicenter International Studies on the Treatment of Aggressive Lymphomas; Mito, mitoxantrone; MTX, methotrexate; NHLCSG, non-Hodgkin Lymphoma Cooperative Study Group; NR, No response; NRM, non-
relapse mortality; OR, odds ratio; OS, overall survival; PB, peripheral blood; PBSCT, peripheral blood stem cell transplantation; PD, progressive disease; PR, partial remission; PMBL, primary mediastinal B-cell lymphoma; PS,
performance status; Ref, reference; RR, relative risk; RT, radiation therapy; SC, stem cell; SCT, stem cell transplantation; Seq., sequential; TBI, total body irradiation; TRM, treatment-related mortality; Tx, treatment or therapy;
VACOP-B, etoposide/doxorubicin/cyclophosphamide/vincristine/prednisone/ bleomycin; VCR, vincristine; VP-16, etoposide; y, year.
*Quality and strength of evidence definitions are listed in Table 1.
†TRM only stated for all patients, not by treatment arm.
‡Trial closed in 2003 after a planned interim analysis because of lack of potential to detect relevant differences in OS, high toxicity in HDS arm, and new treatment options for this patient population.
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Table 3. Autologous SCT versus Nontransplantation Therapy for Patients with DLBCL in Partial Remission
Study Design Patient Outcomes
[Ref #], Quality & Strength
of Evidence,* and Patient
Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Group
PControl Therapy Transplant Therapy Disease Characteristic Control Group Transplant Group P Control (n) Transplant (n)
ORIGINAL DLBCL EBR – SCT VERSUS NON-SCT FOR PARTIAL RESPONDERS (NO NEW PUBLISHED DATA)
[18] Verdonck 1995 CHOP HDT +
Auto BMT
CHOP HDT +
Auto BMT
Not stated (3 y, 1.7-7 y) CHOP HDT +
Auto BMT
Diagnoses (35) (34)
1+ 8 CHOP 4 CHOP NHL in PR 100% 100%
(ITT)
1987-1994 Cy + TBI Hist. Subtypes
Multictr, Prospective DLBCL 43% 64% Completed
Post-induction PR n 5 133 Auto BM Immunoblastic 20% 20% Assigned Tx 80% 76%
Eligible for randomization Follicular 17% 4%
n 5 106 Unclass. IG or HG 20% 12% Overall CR 74% 68% .54
Randomized 5 69 (65%)
BM Involvement 6% 11% TRM 0% 6%
Med Age (range)
Not stated (15-60 y) B symptoms 32% 44% 4-year EFS 53 ± 9% 41 ± 10% .43
Bulky Disease 46% 59% 4-year OS 85 ± 6% 56 ± 10% .12
Risk Factors
IPI $3 44% 44%
Stage $III 57% 40%
LDH >Normal 83% 80%
$2 Ex-nodal sites 14% 15%
WHO PS 2-4 6% 9%
Auto indicates autologous; BM(T), bone marrow (transplantation); CHOP, cyclophosphamide/doxorubicin/vincristine/ prednisone; CR, complete remission; Cy, cyclosphosphamide, DLBCL, diffuse large B cell lym-
phoma; EFS, event-free survival; HG, high grade; IG, intermediate grade; IPI, International Prognostic Index; ITT, intention to treat; LDH, lactate dehydrogenase; NHL, Non-Hodgkin lymphoma; PR, partial remission;
OS, overall survival; TBI, total-body irradiation; TRM, treatment-related mortality; Tx, treatment; WHO, World Health Organization.
*Quality and strength of evidence definitions are listed in Table 1.
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Table 4. Autologous SCT versus Nontransplantation as Salvage Therapy for DLBCL
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population
Protocols by Treatment Group Disease Characteristics (at Dx Unless Stated)
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Group
Control Therapy Transplant Therapy Disease Characteristic Control Group Transplant Group P Control (n) Transplant (n) P
ORIGINAL DLBCL EBR PHASE III STUDY OF AUTOLOGOUS BMT AS SALVAGE THERAPY (NO NEW PUBLISHED DATA)
[19] Philip 1995 DHAP HDT +
Auto BMT
DHAP HDT +
Auto BMT
Not stated (5.25 y, Not stated) DHAP HDT +
Auto BMT
Diagnoses (54) (55)
1+ 6 DHAP 2 DHAP IG or HG NHL
in chemosensitive (ITT)
1987-1994 (± RT for bulky dis.) BEAC relapse 100% 100%
PARMA Multictr (51) Completed
Prospective (± RT for bulky dis.) Hist. Subtypes Assigned Tx Not stated 89%
Enrolled n 5 215 DLBCL 65% 75%
Randomized n 5 109 Auto BM Immunoblastic 22% 18% Overall CR 44% 84%
Lymphoblastic 4% 0%
Med Age (range) Indolent 9% 7% TRM 0% 6%
43 y (18-60)
Bulky Disease 41% 29% 5-year EFS 12% 46% .001
LDH >Normal 39% 36% 5-year OS 32% 53% .038
Auto indicates autologous; BEAC, carmustine/etoposide/cyclophosphamide/cytarabine; BM(T), bone marrow (transplantation); CR, complete remission; DHAP, dexamethasone/ cytarabine/cisplatin; DLBCL, diffuse
large B cell lymphoma; EFS, event-free survival; HG, high grade; IG, intermediate grade; ITT, intention to treat; LDH, lactate dehydrogenase; NHL, non-Hodgkin lymphoma; OS, overall survival; RT, radiation therapy;
TRM, treatment-related mortality; Tx, treatment.
*Quality and strength of evidence definitions are listed in Table 1.
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Table 5. Noncomparative Studies of Autologous SCTas Salvage for Patients $60 Years
Study Design Patient Outcomes
(Ref #),Qual. & Strength of
Evidence,* and Patient Population Protocol Disease and Transplant Characteristics
Follow-Up [Med (Range)]
& Patient Outcomes
UPDATE DATA (POST-2000 STUDIES)
[20] Prior Ritux therapy (33%) Diagnoses [1 y (Not stated)]
Jantunen 2008 DLBCL 100%
BEAM (73%)
2+ Status at SCT 3-year NRM 10.8%
TBI in conditioning (1.1%) CR1 23%
2000-2005 CR $2 or PR 71% 3-y Relapse 38%
EBMTR Multictr (525) Auto (99% PBSCT) Untested or refractory 6%
Retrospective 3-year PFS 51%
Pts $ 60 years n 5 463 Prior Chemo Reg $2 76%
3-year OS 60%
Med Age (range) 63 y (60-74) Med Dx to SCT 1.2 y
Bulky Disease 19%
B Symptoms 43%
Risk Factors
Stage $III 72%
LDH >normal 48%
PS $2 4%
[21] HDT: BEAC or BEAM Diagnoses [1.2 y (.1 – 7.3 y)]
Buadi 2006 NHL 100%
Auto (74% PBSCT)
2+ Hist. Subtypes CR/CRu 89%
DLBCL 61%
1995-2003 Transformed FL 26% TRM 5.4%
Single Center MC 7%
Retrospective T cell 4% 4-year EFS 38%
n 5 93 Other 2%
4-year OS 38%
Med Age (range) 66 y (60-76.5) Status at SCT
CR1 5%
PR1 7%
CR2 or PR2 54%
CR or PR >2 31%
Refractory 3%
aaIPI $2 18%
[22] Prior Chemo Diagnoses [1.75 y (Not stated)]
Jantunen 2006 CHOP (77%) NHL 100%
2+ SC Mobilization Hist. Subtypes DLBCL Only
Cy + GF (56%) DLBCL 33%
2000-2005 or Disease-specific chemo + GF MC 31% 100-d TRM 10%
Retrospective Multictr (6) FL 17%
(Continued )
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Biol Blood Marrow Transplant 17:20-47, 2011 35The Role of Cytotoxic Therapy with Hematopoietic SCT in
the Treatment of DLBCLTo briefly summarize, the quality (see Appendix A,
Table 1) of the 11 new studies ranged from 111 to
12. Gisselbrecht et al. [4] reported a significant im-
provementwith full-course chemotherapyversus abbre-
viated chemotherapy 1 autologous SCT on 5-year
event-free survival (EFS) and overall survival (OS), but
only for low- to intermediate-risk patients (age-adjusted
International Prognostic Index [aaIPI] score #2).
Milpied et al. [8] reported a significant positive impact
of abbreviated chemotherapy1 autologous SCT versus
full-course chemotherapy on 5-year EFS, but only
for intermediate-high to high-risk patients (aaIPI $3).
The remaining seven studies [5-7,9-12] found no
significant differences in outcomes between the
autologous SCT and nontransplantation groups. Both
meta-analyses [2,3] of published evidence reported
that first-line autologous SCT did not consistently
provide benefits in OS or EFS when compared with
conventional chemotherapy overall or in patients with
a low IPI score. The evidence for high IPI score patients
was inconclusive because of conflicting results.
Of the three randomized studies from the original
DLBCLEBR,Haioun et al. [13] reported a statistically
significant advantage in 8-year DFS and OS, and
Gianni et al. [17] reported an advantage in 7-year
EFS (OS approached significance), for patients who
underwent autologous SCT versus nontransplantation
therapy. Santini et al. [16] reported a better 6-year
DFS rate among patients who underwent autologous
SCT versus nontransplantation therapy, but the differ-
ence was not statistically significant.
Autologous SCT versus Nontransplantation
for Patients in Partial Remission
There arenonewrandomized studieson the efficacy
of autologous SCT versus chemotherapy for patients in
partial remission following first-line induction therapy
for DLBCL. One Phase III study by Verdonck et al.
[18] from the original EBR compared the use of autolo-
gous SCT versus chemotherapy (CHOP) as treatment
for patients in partial remission after three cycles of
first-line chemotherapy and found no significant differ-
ences in OS or EFS between the two treatment groups.
Table 3 presents the details of the study design and out-
comes according to the new format and grading criteria.
Autologous SCT versus Nontransplantation
as Salvage Therapy
The 1995 PARMA trial discussed in the original
DLBCL EBR remains the only randomized trial com-
paring autologous SCT versus salvage chemotherapy
to date; details of the study design and outcomes are
presented in Table 4 according to the new format
and grading criteria [19]. The study reported a signifi-
cantly superior OS and EFS in patients who under-
went salvage autologous SCT. Based on this study,
36 Biol Blood Marrow Transplant 17:20-47, 2011D. M. Oliansky et al.autologous SCT has become the standard of care in
patients \60 years with chemosensitive relapsed or
primary refractory aggressive non-Hodgkin lym-
phoma (NHL).AUTOLOGOUS SCT FOR PATIENTS $60
YEARS OF AGE
The PARMA trial [19] did not enroll patients over
60 years, and there are no comparative data of autolo-
gous SCT versus nontransplantation as salvage therapy
in this patient group. There are three cohort studies
[20-22] published since the original review of
autologous SCT as salvage therapy for patients $60
years. Because of the prognostic importance of age,
these noncomparative studies are included in the main
article. Table 5 summarizes the study designs, patient
populations, and outcomes from these noncomparative
studies as evidence on the use of autologous SCT as sal-
vage for patients $60 years of age.AUTOLOGOUS VERSUS ALLOGENEIC SCT
It was noted in the original DLBCL EBR that there
were comparative studies of autologous versus allogeneic
SCT in NHL patients that would have provided much
needed evidence in this area, but they were not included
in the EBRbecause they did not report the proportion of
DLBCLpatients in their study populations. Presented in
this update are two nonrandomized studies published
since 2000 that compared the outcomes of autologous
versusmyeloablative allogeneic SCTas treatment specif-
ically for DLBCL patients. The quality ratings of these
studieswere 211 and 21. Table 6 summarizes the study
designs, patientpopulations, andoutcomes fromthisnew
evidence.Lazaruset al. [23] reported that allogeneicSCT
patients had significantly worse 1-year probabilities of
OS, progression-free survival (PFS), and treatment-
related mortality (TRM) compared to autologous SCT
patients, but the differences were not significant at 3 or
5 years. Aksentijevich et al. [24] reported a significantly
worse 3-year TRM for allogeneic compared to autolo-
gous SCT patients, but no difference in survival out-
comes. Neither study reported a significant difference
in risk of relapse or disease progression between the
two treatment groups at any time interval.AUTOLOGOUS SCT
The autologous SCT section of this DLBCL up-
date is composed of 15 comparative and 36 noncompar-
ative studies. The original DLBCL EBR contained no
studies that examined the impact of rituximab therapy
in combination with autologous SCT. Published since
2000 were 10 comparative studies examining the use
of rituximab as part of autologous SCT, includingtwo randomized trials and eight cohort studies. Rituxi-
mab has changed the biology of relapsed DLBCL by
improving the cure rate after induction therapy, but
may result in relapsed disease that is more resistant to
salvage therapy. Because rituximab is now the standard
of care in the therapy of DLBCL, studies on the use of
rituximab prior to autologous SCT are not useful for
making treatment recommendations, but may help de-
termine post-autologous SCT prognosis.
Comparative Studies of Autologous SCT
Table 7 presents the study designs and outcomes of
three comparative studies used to make treatment rec-
ommendations on: autologous BMT versus autolo-
gous PBSCT [25], the use of rituximab after
autologous SCT [26], and fewer versus more courses
of induction therapy prior to autologous SCT [27].
These studies, whose quality ratings ranged from
111 to 2, are briefly summarized later.
Appendix B (online only) presents the details of the
12 comparative studies of autologous SCT that were
not used in the development of the treatment recom-
mendations because of the obsolete or peripheral
nature of their findings. These included nine studies
of rituximab use prior to, or before and after, autolo-
gous SCT [32-40], timing of transplantation [41], in-
tensity of stem cell mobilization regimen [42], and
the use of oral versus intravenous busulfan as high-
dose therapy prior to autologous SCT [43].
Autologous bond marrow transplantation (BMT)
versus peripheral blood stem cell transplantation
(PBSCT)
A randomized study by Vose et al. [25], published
after the original EBR, compared autologous PBSCT
versus BMT as treatment for aggressive non-Hodgkin
lymphoma (NHL) patients (61% DLBCL). The qual-
ity rating of this study is 111. Patients who underwent
autologous PBSCT had a significantly longer OS, but
not EFS, compared to autologous BMT patients.
Rituximab as maintenance therapy after
autologous SCT
Whether to use rituximab as routine maintenance
therapy post-SCT remains an important clinical ques-
tion.A studybyHaiounet al. [26] reportedno significant
difference in EFS among patients who received mainte-
nance rituximab therapy versus those who did not.
Fewer versus more cycles of induction therapy
prior to first-line autologous SCT
Van Imhoff et al. [27] investigated the impact of
three courses of intensified CHOP versus no CHOP
prior to two cycles of induction followed by first-line
autologous SCT for patients with de novo aggressive
NHL, and found that patients who received the
Table 6. Autologous versus Allogeneic SCTas First-Line or Salvage Therapy for DLBCL
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence*,
and Patient Population
Protocols by Treatment Group Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Group
PControl Therapy Transplant Therapy
Disease
Characteristic Control Group Transplant Group P Control (n) Transplant (n)
UPDATE DATA (POST-2000 STUDIES)
(Myeloablative) Auto Allo Auto Auto SCT Allo SCT
[23] Auto SCT Allo SCT SCT SCT (5 y, .08 - 10.8 y) (837) (79)
Lazarus 2010 Diagnoses
BEAM/similar (61%) TBI + Cy (52%) DLBCL 100% 100% Allo
2++ TBI-based (18%) Bu + Cy (30%) (6.75 y,1.2-10 y)
CBV/similar (10%) Other (18%) Disease Status at SCT <.001
1995-2003 Other (11%) Primary Induct Failure 29% 51% 3-year TRM 16% 43% >.05
CIBMTR Multictr (156) CR1 18% 7% CI 14%-19% CI 32-51%
Retrospective BM (9%) BM (37%) $CR2 17% 8%
n 5 916 HLA-identical sibling Relapsed- sensitive 29% 18% 3-year PFS 47% 24% >.05
Relapsed - resistant 7% 16% CI 43%-50% CI 15%-34%
Med Age (range)
Auto 48 y (18-60) BM Involvement 17% 42% <.001 3-year OS 53% 26% >.05
Allo 46 y (21-59) CI 49%-56% CI 17%-36%
(P 5 .05) B symptoms 46% 58% .04
3-year Relapse 40% 33% >.05
Med Dx to SCT 1.1 y .92 y .03 CI 36%-43% CI 23%-43%
(range) (.17-23.9 y) (1.7-13 y)
Prior Chemo Reg >2 41% 51% .12
Risk Factors
aaIPI $3 52% 71% .02
Stage $III 66% 80% .003
$2 Ex-nodal sites 57% 70% .02
Karnofsky PS <90 36% 44% .18
[24] (Myeloablative) Auto Allo
Aksentijevich 2006 Auto SCT Allo SCT SCT SCT Auto Auto SCT Allo SCT
Diagnoses (5.2 y,1.1-16.6 y) (138) (45)
2+ TBI + Cy (66%) TBI + Cy (38%) DLBCL 100% 100% Allo
Bu + Cy (25%) Bu + Cy (49%)
1985-2001 BuCy + VP-16 (9%) BuCy + VP-16 (13%) Disease Status at SCT .004 (4.2 y,1.2-14 y)
Single Center Sensitive 51% 29%
Retrospective 4-HC purged (59%) BM T cell-depleted BM Resistant 49% 71%
n 5 183 or PBSC HLA-matched sibling
B symptoms 23% 36% .08 3-year TRM 23.9% 51.1% .001
Med Age (range)
Auto 45 y (18-67) Med Dx to SCT 1 y .96 y .70 3-year EFS 30.9% 19.1% .20
Allo 36 y (18-59) (range) (.1-10.7 y) (.3-6.5 y)
(P < .001) 3-year OS 33.1% 23.7% .17
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38 Biol Blood Marrow Transplant 17:20-47, 2011D. M. Oliansky et al.intensifiedCHOPhad significantly better OS and EFS
than those who did not.
Noncomparative Studies of Autologous SCT
The 36 noncomparative cohort studies included in
this update examined the use of autologous SCT as
first-line (11 studies) or salvage (25 studies) therapy
for DLBCL [44-77].
The design, methodology, and outcomes data from
these studies are summarized in Appendix C (online
only). These studies represented nonrandomized sin-
gle- or multi-institutional experiences with autologous
SCT or retrospective analyses of transplantation regis-
try data. The quality ratings of the noncomparative
autologous SCT studies ranged from 211 to 22.
Collectively, the outcomes data from these studies con-
tribute to the overall understanding of the effectiveness
of autologous SCT in the treatment of DLBCL. One
treatment recommendation was developed from several
noncomparative Phase II studies on the use of tandem
or multiple autologous SCTs [44-47].ALLOGENEIC SCT
There were no comparative studies in the original
EBR, which examined reduced intensity conditioning
(RIC) versus myeloablative (MA) conditioning for allo-
geneic SCT. There is one comparative and five non-
comparative allogeneic SCT studies published since
2000 included in this update. Rodriguez et al. [28] re-
ported that patients who received RIC versus MA con-
ditioning prior to allogeneic SCT had significantly
higher relapse rates, but no difference in OS or PFS.
The quality of this study was a 21, andTable 8 presents
a detailed summary of the study design and outcomes.
Appendix D (online only) summarizes the five non-
comparative studies published since the original review,
which reported treatment outcomes after either MA
(n 5 1) or RIC (n 5 4) prior to allogeneic SCT
[78-82]. The study quality ratings ranged from 211 to
21. These studies represent nonrandomized single- or
multi-institutional experiences with allogeneic SCT or
retrospective analyses of transplantation registry data.
Although they contribute to the overall understanding
of the effectiveness of allogeneic SCT in the treatment
of DLBCL, as noncomparative studies they were not
used for making a treatment recommendation regarding
conditioning intensity for allogeneic SCT.AREAS OF NEEDED RESEARCH AND
ONGOING STUDIES
After reviewing the updated evidence on the use of
SCTforDLBCL, the expert panel identified several im-
portant areas of needed research. As noted, some identi-
fied areas of needed research are being investigated by
Table 7. Comparative Studies of Autologous SCT for DLBCL
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence*,
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
UPDATE DATA (POST-2000 STUDIES)
AUTOLOGOUS BMT VERSUS PBSCT
[25] Auto Auto Auto
Vose, 2002 Auto BMT Auto PBSCT BMT PBSCT (4.6 y, 2.6-7.0 y) Auto BMT PBSCT
Diagnoses (46) (47)
1++ BEAC BEAC Aggressive NHL 100% 100%
+ GF for mobilization (ITT)
1993-1997 Hist. Subtypes >.05
Multicenter (5) Auto BMT Auto PBSCT DLBCL 61% 62% Overall CR 54% 72% .09
Enrolled n5105 followed by GF followed by GF Immunoblastic 22% 17%
Randomized n593 Composite 6% 13% 4-year EFS 37% 37% .39
Unclassified 11% 8% CI 23%-51% CI 23%-51%
Med Age (range)
BMT 44 y (18-69) Disease Status at SCT >.05 4-year OS 43% 61% .037
PBSCT 49 y (22-72) PIF/Rel Sensitive 60% 64% CI 29%-58% CI 47%-75%
(P >.05) PIF/Rel Resistant 7% 9%
CR1 9% 9%
CR2 13% 12%
Untreated Relapse 11% 6%
Prior Chemo Reg >2 13% 32% .046
Bulky disease 7% 6% >.05
Risk Factors
Stage $III 53% 60% >.05
LDH >Normal 26% 30% >.05
High Risk 15% 13% >.05
RITUXIMAB VERSUS NO RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS SCT FOR DE NOVO DLBCL
[26] No Ritux Ritux No Ritux Ritux All No Ritux Ritux
Haioun 2009 Diagnoses >.05 (4 y, Not stated) (130) (139)
Randomized Induction Randomized Induction Aggressive DLBCL 100% 100%
1+ ACVBP or AC/ACE ACVBP or AC/ACE
BM Involvement 24% 24% 2-year EFS 71% 80% .099
1999-2004 HDT HDT CI 62%-78% CI 72%-86%
Multictr (40) Mito + Cy + VP-16 Mito + Cy + VP-16 Bulky disease 36% 40%
Enrolled n 5 476 + Carmustine + Carmustine
SCTeligible n 5 402 Risk Factors
2nd Randomization n 5 269 Auto SCT Auto SCT aaIPI $3 100% 100%
(Continued )
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Table 7. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence*,
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
Stage $III 97% 97%
Med Age (range) 2nd randomization
to observation
2nd randomization
to 4x Ritux
$2 Ex-nodal sites 66% 60%
No Ritux 47 y (18-59)
LDH >Normal 93% 95%Ritux 47 y (19-59)
PS $2 35% 29%
FEWER VERSUS MORE CYCLES OF INDUCTION THERAPY PRIOR TO FIRST-LINE AUTOLOGOUS SCT
[27] No CHOP CHOP No CHOP CHOP No CHOP No CHOP CHOP
Van Imhoff 2005 (HOVON-27) (HOVON-40) (HOVON-27) (HOVON-40) (6.9 y, 4.2-9.3 y) (HOVON-27)
(66)
(HOVON-40)
(81)
2++ 3 CHOP Diagnoses CHOP
de novo aggress. NHL 100% 100% (2.8 y, 1.1-4.9 y)
1994-1999 HDS Therapy HDS Therapy
HOVON-27 trial Cy + Dox + Pred Cy + Dox + Pred Hist. Subtypes .54
1999-2001 + GF + GF DLBCL 76% 83% TRM 9% 6%
HOVON-40 trial Y Y FL 9% 4%
Multictr VP-16 + Mito + Pred VP-16 + Mito + Pred Anaplastic LCL 9% 5% 4-year EFS 15% 49% <.001
Retrospective + GF + GF T cell 5% 6% CI 8%-25% CI 38%-59%
Total n 5 395 Unclassified 2% 2%
HDT HDT 4-year OS 21% 50% .007
Med Age (range) BEAM BEAM B Symptoms 79% 81% .68 CI 12%-32% CI 37%-61%
No CHOP 49 y (15-64)
CHOP 52 y (18-65) Auto PBSCT Auto PBSCT Bulky Disease 45% 33% .17
(P 5 .62) ± RT ± RT
Risk Factors
aaIPI $2 100% 100%
Stage $III 100% 100%
LDH $ Normal 98% 100%
>1 Ex-nodal sites 47% 32% .13
PS $2 35% 20% .04
aaIPI indicates age-adjusted International Prognostic Index; Ara-C, cytarabine; Auto; autologous; BEAC, carmustine/etoposide/cyclophosphamide/cytarabine; BEAM, carmustine/etoposide/cytarabine/melphalan; BMT,
bone marrow transplantation; Bu, Busulfan; CBV, cyclophosphamide/carmustine/etoposide; CHOP, cyclophophamide/ doxorubicin/vincristine/prednisone; CI, 95% confidence interval; CR, complete remission; Cy,
cyclosphosphamide; DLBCL, diffuse large B cell lymphoma; Dox, doxorubicin; Dx, diagnosis; EFS, event-free survival; ESHAP, etoposide/cytarabine/methylprednisolone/cisplatin; FL, follicular lymphoma; GF, growth
factor; HDS, high-dose sequential therapy; HDT, high-dose therapy; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; HR, high risk; IPI, International Prognostic Index; IV, Intravenous; LDH, lactate
dehydrogenase; mAbs, monoclonal antibodies; MC, mantle cell; Mito, mitoxantrone; NHL, non-Hodgkin Lymphoma; PBSCT, peripheral blood stem cell transplantation; PFS, progression-free survival; PIF, primary
induction failure; PR, partial remission; Pred, prednisone; PS, performance status; OS, overall survival; R or Ritux, rituximab; RT, radiation therapy; SCT, stem cell transplantation; TBI, total-body irradiation; TILC,
time interval since last chemotherapy; TRM, treatment-related mortality; Tx, treatment, VP-16, etoposide.
*Quality and strength of evidence definitions are listed in Table 1.
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Table 8. Comparative Study of Allogeneic SCT for DLBCL
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease Characteristic Treatment Groups P (n) (n) P
UPDATE DATA (POST-2000 STUDY)
MYELOABLATIVE VERSUS REDUCED-INTENSITY CONDITIONING FOR ALLOGENEIC SCT
[28] CMR RIC CMR RIC CMR CMR RIC
Rodriguez 2006 (5.8 y, 2.8-8.1 y) (48) (40)
Conditioning Conditioning Diagnoses
2+ f-TBI + Cy (85%) or Flu + Mel NHL 100% 100% RIC
Bu + Cy (15%) (1.7 y, .5-3.5 y)
1991-2000—CMR Pts. Hist. Subtypes
2000-2003—RIC Pts. Donors Donors Low grade B cell 33% 30%
Single Center MUD (17%) MUD (43%) Intermed grade B cell 38% 40% Overall
Retrospective (including DLBCL & 1-year TRM 0% 6%
Total n 5 88 SC Source SC Source transformed DLBCL)
Int. grade B cell n 5 28 PBSC (33%) PBSC (90%) Mantle cell 21% 13% Int Grade Only
(Stratified) T cell 8% 17% 2-year PFS 44% 31% .18
Allo SCT Allo SCT
Med Age (range) Prior Auto SCT 10% 40% .002 2-year OS 50% 36% .56
CMR 44 y (18-54)
RIC 51 y (20-67) Med Prior Chemo Reg 3 2 .02 2-year Relapse 12% 44% .02
Chemosensitive at
SCT 50% 78% .007
Allo indicates allogeneic; Auto, autologous; Bu, busulfan; Chemo, chemotherapy; CMR, conventional myeloablative regimens; CR, Complete remission; Cy, cyclosphosphamide, DLBCL, diffuse large B cell lymphoma;
Flu, fludarabine; f-TBI, fractionated total-body irradiation; Mel, melphalan; MUD, matched unrelated donor; NHL, Non-Hodgkin lymphoma; PBSC, peripheral blood stem cells; PFS, progression-free survival; RIC,
reduced-intensity conditioning; OS, overall survival; SCT, stem cell transplantation; TRM, treatment-related mortality.
*Quality and strength of evidence definitions are listed in Table 1.
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42 Biol Blood Marrow Transplant 17:20-47, 2011D. M. Oliansky et al.new trials or ongoing studies that are currently accruing
patients, maturing follow-up, or have been published in
abstract form. None of the data described below was
used as evidence for the review or for making treatment
recommendations. This section is provided for the
reader’s information only.Induction
 Identify more effective induction regimens to
optimize disease response and reduce the need for
autologous SCT.
There are no ongoing studies that address this area
of needed research.
 Identify and examine the efficacy of predictive
tests (ie, PET scanning) to classify patients who are at
high risk for early treatment failure (those who are
primary refractory to initial therapies and those who
respond but quickly relapse) and candidates for
autologous SCT.
Trneny et al. [29] prospectively recorded the PET
scans at the end of induction treatment in 123 patients
with relapsed or refractory DLBCL enrolled in the
CORAL study. PET was negative in 61 patients and
positive in 62. Of these, 60 and 58 patients completed
three cycles of RICE or RDHAP, with 50 PET2 and
26 PET1 patients receiving BEAM 1 autologous
SCT. Intent-to-treat analysis found a significant
improvement in for 3-year EFS (40% versus 16%,
P\.0001) and 3-year OS (66% versus 49%, P5 .007)
for PET2 and PET1 patients, respectively. For pa-
tients who underwent autologous SCT, there was a sig-
nificant improvement in EFS (P5 .03) for PET2, but
no signficant difference in PFS or OS.
 Update the IPI to include molecular markers
and/or gene expression profiling to better
discriminate prognostic groups that would benefit
from SCT.
There are no ongoing studies that address this area
of needed research.
 Determine the potential benefit of first-line
autologous SCT for patients with central nervous
system involvement.
There are no ongoing studies that address this area
of needed research.Salvage after Induction Failure
 Identify effective salvage regimens to optimize
disease response prior to autologous SCT.
Gisselbrecht et al. [30] presented the preliminary
intent-to-treat analysis of 396 patients enrolled in
the ongoing multicenter intergroup Phase IIICollaborativeTrial inRelapsedAggressiveLymphoma
(CORAL) study, which began in 2003 in 11 countries
and investigated the choice of salvage therapy in refrac-
tory or relapsed DLBCL. Patients were randomized to
receive three cycles of RICE or RDHAP, and re-
sponders were treated by autologous SCT with
BEAM. Autologous SCT was performed in 206 pa-
tients. No difference was found between RICE and
RDHAP in response rate (63.5%, confidence interval
[CI] 56%-70% versus 62.8%, CI 55%-69%) or 3-
year EFS (26% versus 35%, P 5 .60). Three-year
EFS was negatively affected by prior exposure to ritux-
imab versus no exposure (21% versus 47%, P\.0001).
At amedian follow-up of 27months,Mounier et al.
[31] presented the findings of a GELA Phase II (LNH-
2003-3) case-controlled study of the survival benefit of
intensive high dose therapy with rituximab 1 ACVBP
followed by BEAM and autologous PBSCT versus
ACVBP 1 autologous PBSCT. From 2004 to 2005,
209 patients received the R1ACVBP regimen and
were matched with patients from the LNH-98-3 trial
who received the ACVBP regimen. Intent-to-treat 3-
year PFS was significantly higher in the R1ACVBP
than in the ACVBP arm (75% versus 58%, P 5
.0003), as was the estimated 3-year OS (78% versus
67%, P 5 .05).
High-Dose Therapy Regimens with Autologous
SCT
 Identify effective high dose therapy regimens to
optimize complete response, improve hematopoietic
recovery, and reduce TRM and incidence
of secondary disease.
The Bone Marrow Transplant-Clinical Trials
Network (BMT-CTN) has sponsored a randomized,
Phase III trial (Protocol 0401) that compares the
high-dose regimens rituximab 1 BEAM versus I131-
tositumomab 1 BEAM followed by autologous SCT
in adult (18-80 years) patients with persistent or recur-
rent chemotherapy-sensitive DLBCL. A total of 224
patients have been accrued. The primary outcome
measure is PFS, with secondary outcome measures in-
cluding OS, time to progression, complete response,
and partial response at day 100, time to hematopoietic
recovery, hematologic function, toxicity, TRM, and
incidence of secondary disease.
TheM.D. Anderson Cancer Center has sponsored
a randomized trial (NCT00472056) comparing stan-
dard (375 mg/m2) versus high-dose (1000 mg/m2) rit-
uximab 1 BEAM followed by autologous SCT in
adult (up to 80 years) patients with relapsed DLBCL.
A total accrual of 100 patients is projected. DFS in
the two treatment arms is the primary outcome mea-
sure for patients 65 years or younger; DFS and TRM
are the outcome measures of interest for patients
older than 65 years.
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randomized trial (NCT00591630) compares 90Y-
ibritumomab tiuxetan 1 BEAM 1 rituximab versus
BEAM1 rituximab with or without rituximab mainte-
nance (applicable to next section) after autologous
SCT for adult (18-70 years) patients with relapsed,
chemotherapy-sensitive DLBCL. A total accrual of
100 patients is projected, and PFS is the primary out-
come measure.
Maintenance Therapy After Autologous SCT
 Identify effective maintenance regimens
to optimize disease control post-autologous SCT.
The Gisselbrecht et al. CORAL study identified
above [30] also investigated the role of rituximabmain-
tenance after autologous SCT. A second randomiza-
tion after autologous SCT allocated patients to
observation or maintenance therapy with rituximab
for one year. Longer follow-up is needed for the anal-
ysis of this second randomization.
The Eastern Cooperative Oncology Group
(ECOG) has sponsored a randomized, multicenter,
Phase III trial (NCT00052923) comparing autologous
SCT with or without rituximab maintenance for adult
(18-70 years) patients with relapsed or progressive
DLBCL. A total accrual of 427 patients is projected;
OS and TRM are the primary outcome measures.
CureTech Ltd. has sponsored a Phase II, multi-
center study (NCT00532259) with Northwestern
University investigating the safety and efficacy of the
monoclonal antibody CT-011 as maintenance therapy
following autologous PBSCT in adult patients (181
years) with relapsed DLBCL. A total of 70 patients
has been accrued; PFS, EFS, OS, and toxicity are the
outcome measures of interest.
The Case Comprehensive Cancer Center has spon-
sored a Phase I/II trial (NCT01045928) investigating
the efficacy and best dose of lenalidomide 1 rituximab
as maintenance therapy after autologous SCT for adult
(181 years) patients with B cell NHL, including
DLBCL patients. Expected enrollment is 71 patients.
Primary outcomes measures are maximum tolerated
dose and safety of lenalidomide 1 rituximab (Phase I)
and tolerability of the maintenance therapy (Phase II);
a secondary outcome measure is PFS (Phase II).
The University of Nebraska has sponsored a Phase
I/II trial (NCT01035463), investigating the efficacy
and best dose of lenalidomide as maintenance therapy
after combination chemotherapy with or without
rituximab and autologous SCT for adult (191 years)
patients with persistent or recurrent NHL that is resis-
tant to chemotherapy. Expected enrollment is 44 pa-
tients. Primary outcome measures are maximum
tolerated dose and toxicity of lenalidomide (Phase I);
secondary outcome measures are OS, EFS, and com-
plete response rate (Phase II).The FredHutchinsonCancer Research Center has
sponsored a Phase II trial (NCT00992446) investigat-
ing the efficacy and safety of bortezomib and vorino-
stat as maintenance therapy after autologous SCT in
adult (181 years) patients with NHL, including
DLBCL patients. Estimated enrollment is 20 patients,
and time to progression and toxicity are the outcome
measures of interest.
Salvage after Failed SCT
 Examine the efficacy of reduced intensity
allogeneic SCTas rescue after a failed autologous
SCT.
There are no ongoing studies that address this area
of needed research.
Other Ongoing Studies
The following are ongoing studies that did not re-
late to any of the areas of needed research suggested by
the expert panel, but whose future outcomesmay affect
treatment recommendations.
Autologous SCT versus Non-SCT Therapy
The Southwest Oncology Group (SWOG) has
sponsored a randomized, multicenter, Phase III trial
(NCT00004031) comparing the effectiveness of stan-
dard CHOP 6 R (8 cycles) versus CHOP 6 R (6
cycles) followed by autologous PBSCT with total body
irradiation (TBI)-based regimens for treating adult (15-
65 years) patients with diffuse aggressive intermediate/
high grade NHL. Patients in the CHOP 6 R arm can
cross over to the SCT arm at the time of disease progres-
sion. The target accrual is 360 patients; OS and PFS are
the primary outcome measures.
The British National Lymphoma Investigation has
sponsored a randomized, multicenter, Phase III trial
(NCT00003578) comparing the effectiveness of high
dose chemotherapy alone versus SCT as part of planned
initial therapy for adult (16-65 years) patients with poor
risk intermediate/high grade NHL, including DLBCL
patients. A total accrual of 500 patients is projected.
Reduced-intensity allogeneic SCT
as consolidation after autologous SCT
Stanford University and the National Institutes of
Health have sponsored a Phase II, non-randomized
trial (NCT00482053) investigating a nonmyeloabla-
tive conditioning regimen of total lymphoid irradia-
tion and antithymocyte globulin (ATG) followed by
an HLA-matched allogeneic SCT as consolidation
after autologous SCT in adult (18-70 years) patients
with poor risk recurrent or primary refractory
DLBCL. The estimated enrollment is 30 patients. Pri-
mary outcome measures are EFS and toxicity; OS and
TRM are secondary outcome measures.
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M.D. Anderson Cancer Center has sponsored
a single-center study (NCT00880815) investigating
the efficacy of a nonmyeloablative regimen of fludara-
bine, bendamustine, and rituximab as conditioning
prior to allogeneic SCT for adult (18-70 years) pa-
tients with lymphoid malignancies, including DLBCL
patients who are not eligible for autologous SCT and
who have an HLA-matched sibling donor. The pro-
jected accrual is 46 patients, and the primary outcome
measure is maximum tolerated dose and toxicity.STRENGTHS/LIMITATIONS AND
DISCUSSION
The strengths of this updated systematic evidence-
based review are the details about each study’s design
and outcomes conveyed in the summary tables for
each major section, and the treatment recommenda-
tions made by the DLBCL expert panel. A limitation
is the exclusion of nonpeer-reviewed data. Unpub-
lished data can represent ‘‘negative’’ findings that
could lead to publication bias; however, the inclusion
of high-quality, peer-reviewed publicly available data
was of paramount importance. Except in the Ongoing
Studies section, data published in abstract form were
not included in this review because of the inadequate
details of study design or patient characteristics, mak-
ing a true assessment of the widespread applicability or
impact of the treatment outside the scope of the trial
difficult.
A limitation of the DLBCL EBR Update is that
much of the newly presented data is already obsolete
in terms of the current standard of care, stressing the
need for more timely updates of the EBRs. For exam-
ple, an abundance of research on the effectiveness of
rituximab prior to autologous SCT has been published
since the original DLBCL EBR, but as rituximab is
now the current standard of care, these studies are
not useful for making treatment recommendations.
In addition, the lengthy process of conducting and
reporting clinical research emphasizes the need to
identify surrogate endpoints or molecular markers
that are predictive of long-term survival in DLBCL
patients. Further delineation of clinical risk factors
may facilitate appropriate selection of DLBCL pa-
tients for autologous versus allogeneic SCT.ACKNOWLEDGMENTS
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EVIDENCE-BASED REVIEW UPDATE
Introduction
In 1999, the American Society for Blood and Mar-
row Transplantation (ASBMT) began developing sys-
tematic evidence-based reviews (EBR) and position
statements on the effectiveness of autologous and allo-
geneic hematopoietic stem cell transplantation (SCT)
for specific diseases. The purpose of these reviews is
to provide evidence in support of clinical decisions
and matters of public policy regarding SCT and
achieve broader and more consistent coverage from
payers for established indications for SCT. The
ASBMT EBR Steering Committee developed specific
policies outlining the methodology to be followed for
these reviews [1,2]. Currently, eight reviews have
been published in Biology of Blood and Marrow
Transplantation (BBMT) on the use of SCT in the
therapy of: diffuse large B cell lymphoma (DLBCL)
[3], multiple myeloma [4], pediatric acute lymphoblas-
tic leukemia (ALL) [5], adult ALL [6], pediatric acute
myelogenous leukemia (AML) [7], adult AML [8],
myelodysplastic syndromes (MDS) [9], and follicular
lymphoma [10].
In 2009, the ASBMT EBR Steering Committee
determined that previously published reviews should
be updated regularly at approximately five-year inter-
vals. The purpose of the updates is to provide a sum-
mary of recent clinical evidence, provide timely
treatment recommendations, and determine if new
evidence strengthens or changes the treatment recom-
mendations provided in the original EBR. By provid-
ing these updates, physicians will have access to
timely information that will facilitate and help dissem-
inate advances in the field of transplantation. To guide
its own activities and that of the expert panel associated
with each review, the ASBMTEBR Steering Commit-
tee developed a policy statement specifying the meth-
odology to be followed for updating each review [11].
The same expert panel members associated with the
original EBR are invited to participate in the update
process as well.
Expert Panel Selection for EBRs
To achieve an appropriate balance, physicians who
have extensive clinical experience and published re-
search studies using SCT and other therapies in the
treatment of the specific disease of interest are invited
to join an independent expert panel that examines the
summarized literature and provides subsequent treat-
ment recommendations based on the available evi-
dence. Potential panelists are restricted to U.S.-based
institutions for 2 reasons: (1) ease of logistics in con-
vening teleconferences, and (2) differences in the
health care systems and health insurance coveragebetween theUnited States and other countries (includ-
ing Canada, Europe, etc.), which may result in differ-
ent expert recommendations based on considerations
of costs and access to care. In addition to clinical and
research physicians, at least one third-party payer rep-
resentative, a patient advocate, and a liaison to the
ASBMT Steering Committee are invited to serve on
the panel.
Literature Search Methodology for the DLBCL
Update
PubMed and Medline, the Web sites developed by
the National Center of Biotechnology Information at
the National Library of Medicine of the National In-
stitutes of Health, were first searched on June 10,
2008, using the search terms ‘‘diffuse large B cell lym-
phoma’’ OR ‘‘DLBCL’’ AND ‘‘transplant’’ limited to
‘‘human trials,’’ ‘‘English language,’’ and a publication
date of January 1, 2001, or later. Updated searches
were conducted on April 10, 2009, and November 4,
2009. In addition to the online database searches,
a manual search of the reference lists of the included
articles and relevant reviews published since 2000
was conducted. Papers that were published before
January 2001, included fewer than 25 DLBCL pa-
tients, or were not peer reviewed were excluded. Also
excluded were editorials, letters to the editor, Phase I
(dose escalation or dose finding) studies, reviews, con-
sensus conference papers, practice guidelines, and lab-
oratory studies with no clinical correlates. Unlike the
original DLBCL EBR, abstracts and presentations at
national or international meetings were not used for
the treatment recommendations in this update for
reasons previously described [5]. However, abstracts
are included in the ‘‘Areas of Needed Research and
Ongoing Studies’’ section for the reader’s information.
Many of the studies evaluated for inclusion in this
DLBCL update presented results for high risk or ag-
gressive lymphoma; therefore, to be included, at least
60% of a study’s patients had to have DLBCL, unless
the results were stratified by histologic subtype of
lymphoma.
Qualitative and Quantitative Grading
of the Evidence
The hierarchy of evidence, including a new grading
system for the quality and strength of the evidence and
strength of each treatment recommendation, was pub-
lished as an editorial policy statement in BBMT in
2005 [2]. Appendix A, and Tables 1 and 2, reprinted
from the policy statement, define criteria used to
grade the studies that were included in this update
and criteria to grade the treatment recommendations,
respectively. Study design, including sample size,
patient selection criteria, duration of follow-up, and
treatment protocol also were considered in evaluating
Appendix A, Table 1. Grading the Quality of Design and
Strength of Evidence
Levels of Evidence
1++ High-quality meta-analyses, systematic reviews of randomized
controlled trials (RCTs), or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs
with a low risk of bias
12 Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of
bias
2++ High-quality systematic reviews of case-control or cohort studies. High
quality case-control or cohort studies with a very low risk of confounding,
bias, or chance, and a high probability that the relationship is causal
2+ Well-conducted case-control or cohort studies with a low risk of
confounding, bias, or chance, and a moderate probability that the
relationship is causal
22 Case-control or cohort studies with a high risk of confounding, bias,
or chance, and a significant risk that the relationship is not causal
3 Nonanalytic studies (eg, case reports, case series)
4 Expert opinion
(Reprinted with permission from Harbour R, Miller J. A new system for
grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.)
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the Treatment of DLBCLthe studies. Clinical studies are described in the tables
with sufficient detail to give a concise summary of study
design and patient outcomes.
All data in the text and tables were abstracted from
the original manuscripts by the first author (D.O.) and
double checked for accuracy and clarity by two other
authors (T.H. and P.L.M.).
Some articles contained inconsistencies within the
data reported; the data most consistent with the text of
the article were included in this review.
Format of the DLBCL Update
Evidence is taken from studies published after
2000, which included DLBCL patients 15 years of
age. Studies of ‘‘aggressive lymphoma’’ or ‘‘high-risk
lymphoma’’ patients are included if DLBCL was the
most common subtype included under those broader
terms. For each section of the review, a summary par-
agraph provides an overall description of the number
and types of studies included as evidence, as well as
a brief synopsis of outcomes. As noted earlier, unlikeAppendix A, Table 2. Grading the Strength of the
Treatment Recommendation
Grades of Recommendation
A At least one meta-analysis, systematic review, or randomized controlled
trial (RCT) rated as 1++, and directly applicable to the target population;
or a systematic review of RCTs or a body of evidence consisting principally
of studies rated as 1+, directly applicable to the target population, and
demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to
the target population, and demonstrating overall consistency of results;
or extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the
target population and demonstrating overall consistency of results; or
extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+
(Reprinted with permission from Harbour R, Miller J. A new system
for grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.)the original DLBCL EBR, in which each article was
summarized in detail in the text, this update presents
the study design, patient population, and clinical out-
comes only in the detailed summary tables. The high-
est quality studies are presented in the tables first,
whereas studies of equal quality are presented in
descending order by study population size. When spe-
cific data elements of a study’s patient population or
disease characteristics were not included in a table, it
was because the information was not provided in the
article.
Consensus Process for Treatment
Recommendations
The Treatment Recommendations Table (Table 1
in the DLBCL Update) contains the summary of con-
sensus treatment recommendationsmade by the expert
panel based on the summarized evidence. The consen-
sus process involves a teleconference during which
panelists critically discuss the evidence for each section
of the review and develop initial treatment recommen-
dations according to the categories in Appendix A
Table 2. The information is summarized by the
primary authors in the Treatment Recommendations
Table and distributed to the panelists for additional
review and clarification. Any changes suggested by an
individual panelist are circulated for review and ap-
proval by all panelists. This iterative process concludes
when a final version of the Treatment Recommenda-
tions Table is approved by all panelists.
After the final draft of the review is approved by the
disease-specific expert panel, it undergoes peer review
and is then approved by the EBR Steering Committee
and the ASBMT Executive Committee before submis-
sion to the journal. Any changes requested during the
peer-review process must be reviewed and approved by
all the expert panelists.1. Jones R, Horowitz M, Wall D, et al. ASBMT Policy Statement
regarding themethodology of evidence-based reviews in evaluat-
ing the role of blood andmarrow transplantation in the treatment
of selected diseases. Biol Blood Marrow Transplant. 2000;6:
524-525.
2. Jones R, Nieto Y, Rizzo J, et al. The evolution of the evidence-
based review: evaluating the science enhances the art of
medicine-statement of the Steering Committee for Evidence-
Based Reviews of the American Society for Blood and Marrow
Transplantation. Biol Blood Marrow Transplant. 2005;11:819-822.
3. Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic
therapy with hematopoietic stem cell transplantation in the ther-
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evidence-based review. Biol Blood Marrow Transplant. 2001;7:
308-331.
4. Hahn T,Wingard JR, Anderson KC, et al. The role of cytotoxic
therapy with hematopoietic stem cell transplantation in the ther-
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Appendix B. Comparative Studies of Autologous SCT Not Used for DLBCLTX Recommendations
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
UPDATE DATA (POST-2000 STUDIES)
RITUXIMAB VERSUS NO RITUXIMAB PRIOR TO AUTOLOGOUS SCT FOR DE NOVO OR RELAPSED DLBCL
[32] No Ritux Ritux No Ritux Ritux All (2.6 y, .75-5.6 y) No Ritux Ritux
Vellenga 2008 Diagnoses >.05 (112) (113)
Induction: Induction: Relapsed or refractory
1+ CHOP (83%) CHOP (81%) aggressive NHL 100% 100% (ITT)
Prior Ritux (4%) Prior Ritux (4%)
2000-2005 Hist. Subtypes Completed
HOVON Multicenter Salvage Tx: Salvage Tx: DLBCL 88% 91% assigned Tx 46% 63%
Enrolled n 5 239 DHAP Ritux +DHAP Grade III Follicular 10% 6%
Randomized n 5 225 Other 2% 3% Overall CR 35% 46% .003
VIM Ritux +VIM
Med Age (range) B symptoms 22% 25% 2-year PFS 31% 52% .002
No Ritux 53 y (25-65) HDT: BEAM HDT: BEAM
Ritux 56 y (25-65) Risk Factors 2-year OS 52% 59% .15
Auto SCT Auto SCT aaIPI $3 75% 85%
LDH >Normal 50% 57%
± RT for bulky disease ± RT for bulky disease WHO PS 5 1 38% 35%
[33] No Induction No Induct. Induction (2.4 y,.50-6.9 y) No Induct. Induction
Martin 2008 Ritux Induction Ritux Ritux Ritux Ritux Ritux
Diagnoses (69) (94)
2++ Induction: Induction: Relapsed or refractory
CHOP-like, No Ritux CHOP-like, Ritux DLBCL 100% 100% Completed
2000-2007 HDT & SCT 65.2% 59.6% >.10
GEL/TAMO Multicenter (25) Salvage Tx: Salvage Tx: Prior auto SCT 18.8% 3.2% .001
Retrospective 1-6 Ritux + ESHAP 1-6 Ritux + ESHAP Overall CR 56% 37% .015
Analyzed n 5 163 Prior Chemo Reg $2 29% 8.5% .001
HDT: Mostly BEAM HDT: Mostly BEAM TRM 1.4 2.1 >.10
Med Age (range) Or BEAC or BEAC R-ESHAP cycles $3 72.5% 50% .004
No Ritux 53 y (19-70) 3-year PFS 57% 17% <.001
Ritux 55 y (23-70) Auto SCT Auto SCT Bulky disease 24.6% 30.4% >.10 CI 44%-70% CI 13%-32%
B symptoms 15.8% 30.9% .044 3-year OS 67% 38% <.001
CI 56%-79% CI 25%-51%
Risk Factors
aaIPI $3 6.1% 7.7% >.10
Stage $III 60.8% 62.7% >.10
LDH >Normal 41% 44% >.10
$2 Ex-nodal sites 49.3% 47.9% >.10
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Appendix B. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
[34] No Ritux Ritux No Ritux Ritux No Ritux No Ritux Ritux
Vitolo 2009 (Historical Control) Diagnoses (6 y) (41) (94)
de novo Aggressive 100% 100% Ritux
2++ 8 MACOP-B 4 Ritux+MegaCEOP B cell lymphomas (4.1y)
(Ranges not stated)
2002-2005 2 MAD 2 Ritux + MAD Hist. Subtypes .43
GIMURELL Multicenter DLBCL 85% 86%
Prospective trial n 5 94 ± RT for bulky disease ± RT for bulky disease PMBL 15% 11% (ITT)
1991-1995 Grade IIIb Follicular 0% 3%
Historical Control n 5 41 HDT: BEAM HDT: BEAM Completed
Total analyzed n 5 135 BM Involvement 44% 28% .07 Assigned Tx 76% 81%
Auto PBSCT Auto PBSCT
Med Age (range) B symptoms 59% 48% .492 Overall CR Not stated 82%
No Ritux 46 y (19-59)
Ritux 47 y (19-60) Bulky disease 61% 45% .094 4-year FFS 44% 73% .001
CI not stated CI 63.5%-82.5%
Risk Factors
aaIPI $3 100% 100% 1.00
Stage $III 100% 100% 1.00 4-year OS 54% 80% .002
$2 Ex-nodal sites 54% 35% .056 CI not stated CI 71.6%-88.4%
PS $2 63% 64% 1.00
[35] No Ritux Ritux No Ritux Ritux No Ritux No Ritux Ritux
Fenske 2009 Diagnoses (3.5 y, .08-9.7 y) (818) (176)
Ritux as first-line 38% DLBCL 100% 100%
2+ Ritux as salvage 62% Ritux
Disease Status at SCT .45 (3.5 y, .17-6.9 y)
1996-2003 HDT HDT CR1 17% 22%
CIBMTR Multicenter TBI-based (14%) TBI-based (15%) CR2 16% 20%
Retrospective BEAM or like (64%) BEAM or like (58%) PIF-sensitive 20% 18% 3-year NRM 16% 11% .06
Analyzed n 5 994 CBV or like (9%) CBV or like (15%) PIF-resistant 6% 7%
Bu-Mel/Bu-Cy (6%) Bu-Mel/Bu-Cy (6%) Relapse-sensitive 34% 25% 3-year PFS 38% 50% .008
Med Age (range) Other (7%) Other (6%) Relapse-resistant 7% 8%
No Ritux 52 y (18-75) 3-year OS 45% 57% .006
Ritux 58 y (20-76) Auto PBSCT (92%) Auto PBSCT (94%) Prior Chemo Reg >2 40% 57% < .001
(P < .001) Auto BMT (8%) Auto BMT (6%)
Med Dx to SCT 1.1 y 1.2 y .46
± RT for bulky disease ± RT for bulky disease (range) (.25-17 y) (.17-23 y)
No Ritux as part of conditioning
or as post-SCT maintenance
BM Involvement 5% 2% .06
Bulky disease 35% 27% .23
Risk Factors
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Appendix B. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
aaIPI $3 @ SCT 16% 11% .27
Stage $III 65% 71% .10
Karnofsky PS <90 37% 39% .66
[36] No Ritux (ICE) Ritux (RICE) No Ritux Ritux No Ritux Ritux
Kewalramani 2004 (Historical Control) Diagnoses (2.4 y, Not stated) (147) (36)
Refractory or relapsed
22 3x ICE 3x RICE DLBCL 100% 100%
(included 4x Ritux) Completed assigned Tx 65% 78%
Study years not stated HDT not stated Risk Factors
Single Center HDT: BEAM, Age >60 y 12% 50% .10
Prospective trial n 5 36 Auto SCT TBI + Ifo + VP-16 , aaIPI $2 60% 47% .19 CR post-ICE or RICE 27% 53% .01
Historical control n 5 147 (Details not stated) TBI + Cy + VP-16, or CBV Stage $III 79% 72% .38 CI 20%-34% CI 36%-69%
LDH >Normal 42% 50% .45
Med Age (range) Karnofsky PS <80 34% 22% .23
No Ritux 48 y (18-68) Auto PBSCT Overall
Ritux 45 y (23-72) + GF Response rate 71% 78% .53
2-year PFS 43% 54% .25
CI 34%-55% CI 38%-78%
2-year OS 56% 67% .53
CI 47%-67% CI 50%-89%
[37] No Ritux (LEED) Ritux (R-LEED) No Ritux Ritux Not LEED No Ritux Ritux
Han 2006 Diagnoses Stated (2.4 y) (26) (24)
Induction/Salvage Induction/Salvage aggressive or relapsed R-LEED
22 CHOP for de novo CHOP for de novo NHL 100% 100% (1.5 y)
EPOCH, VADE, or EPOCH, VADE, or (Ranges not stated)
2001-2005 DeVIC for salvage DeVIC for salvage Hist. Subtypes
Single Center DLBCL 50% 75%
Prospective HDT HDT T cell lymphoma 39% 9% TRM 0% 0%
n 5 50 LEED LEED + Ritux MC 8% 0%
(pts >70 y rec’d (pts >70 y rec’d Lymphoblastic 3% 0% PFS 79.6% 66.9% Not stated
Med Age (range) 30% reduction of full 30% reduction of full SLL 0% 4%
No Ritux 63.5 y (28-78) dosage) dosage) FL 0% 4%
Ritux 60 y (42-74) Burkitt 0% 4% OS 78.2% 66.5% Not stated
Auto SCT + GF Auto SCT +GF Intravascular B cell 0% 4%
Disease Status at SCT
CR1 46% 67%
$CR2 23% 16%
PR 27% 17%
Refractory 4% 0%
BM Involvement 23% 17%
Risk Factors
Age >70 y 19% 21%
aaIPI $3 81% 92%
Stage $III 92% 92%
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Appendix B. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
RITUXIMAB VERSUS NO RITUXIMAB BEFORE ANDAFTER AUTO SCT FOR RELAPSED AGGRESSIVE B-CELL NHL
[38] No Ritux Ritux No Ritux Ritux All No Ritux No Ritux Ritux
Khouri 2005 Diagnoses > .05 (2.5 y, .17-8.3 y) (30) (67)
2++ Unspecified chemo 1 Ritux 1 day
prior to unspec.
chemo + GF
aggress. B cell NHL 100% 100%
Ritux
Hist. Subtypes (1.7 y, .17-3.5 y)
2000-2003 DLBCL 57% 61% .40
Single Center PBSC Mobilization PBSC Mobilization FL 43% 39%
Prospective trial n 5 67 Ifo + VP-16 + GF Cy (n 5 34) or TRM 0% 0%
1994-1996 Ifo + VP-16 (n 5 33) Disease Status at SCT
Historical Control n 5 30 + GF + Ritux PIF sensitive 0% 36% <.01 2- year DFS 43% 67% .004
Total analyzed n 5 97 1st relapse, sensitive 80% 51% .01 CI 26%-60% CI 51%-79%
HDT HDT >1st relapse sensitive 17% 7% .30
Med Age (range) BEAM BEAM Stable, untreated 3% 6% .50 2-year OS 53% 80% .002
No Ritux 51 y (27-60) CI 34%-69% CI 65%-89%
Ritux 51 y (20-65) Auto PBSCT + GF Auto PBSCT + GF +
Ritux 1 and 8 days
after PBSCT
Med # Chemo
Reg (range)
2 (2-4) 2 (1-5) .20
Med Dx to SCT (range) 2.1 y
(.67-10 y)
1.8 y
(.33-12 y)
.60
BM Involvement 77% 84% .40
Risk Factors
Age >60 0% 21% .007
IPI $2 at SCT 0% 18% .01
Stage $III 40% 24% .10
LDH >Normal 13% 21% .30
[39] No Ritux Ritux No Ritux Ritux No Ritux Ritux
Tarella 2008 Diagnoses (5 y, Not stated) (396) (349)
2+ HDS HDS HR B Cell NHL 100% 100%
Cy + GF Cy + GF Hist. Subtypes Completed
1986-2005 Y Y DLBCL 73% 67% assigned Tx 90% 87%
GITIL Multicenter (10) MTX + VP-16 + GF 4x Ritux FL 27% 33%
Retrospective Y Y Overall CR 73% 81%
Analyzed n 5 745 ± Ara-C MTX + VP-16 + GF HDS Use
DLBCL n 5 522 (stratified) Y Y First-line therapy 61% 49% TRM 3.3% 2.8% .91
Auto PBSCT ± Ara-C Salvage therapy: 39% 51%
Med Age (range) Y PR 23% 9% DLBCL Only:
No Ritux 44 y (17-65) ± RT for bulky disease Auto PBSCT Ref/Relapsed 77% 91% .002 5-year EFS 53% 58% .006
Ritux 49 y (18-65) Y
2 Ritux Salvage pts who rec’d 5-year OS 57% 63% .005
Ritux in first-line Tx 1% 26%
± RT for bulky disease
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Appendix B. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
HDS Scheme Rec’d < .05
Original 79% 11%
Ara-C supplemented 21% 89%
BM Involvement 28% 39% < .001
Risk Factors
Age $47 y 42% 54% .009
aaIPI $2 59% 63% > .05
[40] No Ritux Ritux No Ritux Ritux Not No Ritux No Ritux Ritux
Kamezaki 2007 Diagnoses Stated (4.3 y) (20) (23)
Induction Induction de novo DLBCL 100% 100% Ritux
22 6 CHOP 6x CHOP + 4 Ritux (2.6 y)
Stage III or IV 100% 100% (Ranges not stated)
2001-2006 PBSC Mobilization PBSC Mobilization
Multicenter VP-16 + GF Ritux + Disease Status at SCT .37
Retrospective VP-16 + GF CR 45% 57% TRM 0% 0%
n 5 43 CRu 40% 30%
HDT HDT PR 15% 13% 1- year PFS 78.3% 80.2% .59
Med Age (range) Ranimustine + Ranimustine +
No Ritux 52 y (15-65) Carboplatin + Carboplatin + Med Dx to SCT .47 y .48 y .43
Ritux 58 y (21-65) VP-16 Ritux + VP-16 (range) (.38-.82 y) (.37-.71 y)
Auto PBSCT+ GF Auto PBSCT + GF
+ Ritux on day -9 and
+ 1 after PBSCT
(Total 8 Ritux)
TIMING OF AUTOLOGOUS SCT
TILC <55 d TILC $55 d
[41] Holtan 2006 TILC <55 d TILC $55 d TILC <55 d TILC $55 d (2.9 y, .08 - 12.1 y) (89) (71)
BEAM (60%) BEAM (52%) Diagnoses
2+ BEAC (37%) BEAC (41%) NHL 100% 100% 5-year PFS 31% 52% <.001
Cy+TBI (3%) Cy+TBI (7%)
1996-2001 Hist. Subgroups 5-year OS 39% 64% <.001
Single Center Auto BMT Auto BMT DLBCL 66% 63% .10
Retrospective analysis FL 14% 21%
n 5 160 T cell 10% 1.5%
MC 7% 13%
Med Age (range) Other 3% 1.5%
TILC < 55 d 52 y (23-73)
TILC $ 55 d 54 y (31-72) Disease Status at SCT .50
(P 5 .96) CR 11% 17%
(Continued )
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Appendix B. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
PR 84% 79%
First relapse 1% 1.5%
Second relapse 2% 0%
Refractory 2% 2.5%
Prior Chemo Reg >2 25% 24% .45
Risk Factors
Age $60 33% 30% .73
IPI $3 14% 7% .62
Stage $III 71% 63% .40
LDH >Normal 34% 28% .49
$2 Ex-nodal sites 6% 3% .02
PS $2 6% 4% .18
INTENSIVE VERSUS NON-INTENSIVE STEM CELL MOBILIZATION PRIOR TO AUTOLOGOUS PBSCT
[42] Damon 2008 Nonintense
(SR for relapse)
Intense
(HR for relapse)
Nonintense Intense (2.5 y, .10-7.6 y) Nonintense
(30)
Intense
(50)
Diagnoses
2+ Salvage Salvage HR NHL 100% 100%
(R)CHOP or ESHAP (R)CHOP or
1999-2005 or Other or None (R)ESHAP or PIF 40% 56% .34 TRM 0% 6%
Single Center (R)ICE or Other
Retrospective analysis or None CR1 <1 year DLBCL only:
N 5 80 (number/evaluable) 6/21 16/28 .04 4-year EFS 51 ± 29% 67 ± 22% .96
SC Mobilization SC Mobilization
Med Age (range) Cy + GF Cy + VP-16 ± Ritux In CR after salvage 48% 35% .23 4-year OS 56 ± 25% 76 ± 20% < .04
Non-Intense 54 y (21-68) or VP-16 + Ara-C
Intense 55 y (23-69) or VP-16 + Ara-C + Ritux Med # Chemo
Reg (range)
2 (1-6) 2 (1-5) .05
Hist. Subtypes
DLBCL 54% (stratified) PBSC Purging PBSC Purging BM Involvement 40% 44% .87
MC 15% ex vivo with mAbs ex vivo with mAbs
LG transformed 12% or in vivo with Ritux or in vivo with Ritux Risk Factors
T-cell 7% ± GF + GF IPI $3 29% 46% .27
Follicular (4%) Stage $III 73% 88% .21
Primary CNS (4%) HDT: CBV HDT: CBV LDH $Normal 40% 68% .01
Burkitt (2%) >1 Ex-nodal sites 28% 36% .44
Intravascular (2%) Auto PBSCT ± GF Auto PBSCT ± GF PS $2 7% 21% .12
(Continued )
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Appendix B. (Continued )
Study Design Patient Outcomes
[Ref #], Quality &
Strength of Evidence,*
and Patient Population Protocols by Treatment Group
Disease (at Dx unless stated) and Transplant Characteristics
Follow-up (Med, Range)
& Pt. Outcomes
Treatment Groups
Disease
Characteristic Treatment Groups P (n) (n) P
COMPARISON OF ORALVERSUS IV BUSULFAN PRIOR TO AUTOLOGOUS SCT
[43] Oral Bu IV Bu Oral Bu IV Bu Not stated (8 y, 7-11 y) Oral Bu
(18)
IV Bu
(31)
Aggarwal 2006 Diagnoses
22 PBSC Mobilization GF PBSC Mobilization
GF ± Cy
HR Aggressive NHL 100% 100%
Hist. Subtypes TRM 28% 3% .01
1994-2003 HDT HDT DLBCL 89% 77%
Single Center Oral Bu + Cy + VP-16 IV Bu + Cy + VP-16 T cell 0% 10% 4-year PFS 17% 50% .008
Retrospective MC 5.5% 7%
Total n 5 49 Auto PBSCT Auto SCT Burkitt 0% 3% 4-year OS 28% 58% .01
(84% PBSCT) Anaplastic 0% 3%
Med Age (range) Immunoblastic 5.5% 0%
Oral Bu 53 y (18-69)
IV Bu 51 y (19-68) Disease Status at SCT
PR1 0% 3%
$CR2 22% 13%
PIF 17% 16%
Relapse—sensitive 39% 39%
Relapse—resistant 5% 16%
Relapse—untreated 17% 13%
# of Chemo Reg >2 94% 81%
Risk Factors
Age >60 y 17% 23%
aaIPI $3 34% 29%
Stage $III 100% 100%
LDH $Normal 33% 29%
Karnofsky PS <90 56% 29%
aaIPI indicates age-adjusted International Prognostic Index; AC/ACE, doxorubicin/cyclophosphamide/etoposide/prednisone; ACVBP, doxorubicin/cyclophosphamide/vindesine/ bleomycin/prednisone; Ara-C, cytarabine;
Auto; autologous; BEAC, carmustine/etoposide/cyclophosphamide/cytarabine; BEAM, carmustine/etoposide/cytarabine/melphalan; BM, bone marrow; Bu, busulfan; CBV, cyclophosphamide/carmustine/etoposide;
CHOP, cyclophophamide/doxorubicin/vincristine/prednisone; CI, 95% confidence interval; CIBMTR, Center for International Blood and Marrow Transplant Research; CR, complete remission; CRu, CR unconfirmed;
Cy, cyclosphosphamide; DeVIC, carboplatin/ etoposide/ifosfamide/dexamethasone; DHAP, cisplatin/cytarabine/dexamethasone; DFS, disease-free survival; DLBCL, diffuse large B cell lymphoma; Dx, diagnosis; EFS,
event-free survival; EPOCH, adriamycin/etoposide/vincristine/cyclophosphamide/prednisone; ESHAP, etoposide/cytarabine/methylprednisolone/cisplatin; FFS, failure-free survival; FL, follicular lymphoma; GEL/TAMO,
Grupo Espan˜ol de linfomas/Trasplante Auto´logo de Me´dula O´sea; GF, growth factor; GIMURELL, Gruppo Italiano Multiregionale Linformi e Leucemie; GITIL, Gruppo Italiano Terapie Innnovative nei Linformi; HDS,
high-dose sequential therapy; HDT, high-dose therapy; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; HR, high risk; ICE, ifosfamide/carboplatin/etoposide; Ifo, ifosphamide; IPI, International Prognostic
Index; LDH, lactate dehydrogenase; LEED, cyclophosphamide/etoposide/ melphalan/dexamethasone; MACOP-B, methotrexate/doxorubicin/cyclophosphamide/vincristine/prednisone/ bleomycin; MAD, mitoxantrone/ cy-
tarabine/dexamethasone; MC, mantle cell; MegaCEOP, cyclophosphamide/epirubicin/vincristine/prednisone; Mel, melphalan; Mito, mitoxantrone; MTX, methotrexate; NHL, non-Hodgkin Lymphoma; NRM, nonrelapsemor-
tality; PBSCT, peripheral blood stem cell transplantation; PFS, progression-free survival; PIF, primary induction failure; PMBL, primary mediastinal B cell lymphoma; PR, partial remission; PS, performance status; OS, overall
survival; RICE, ritux + ICE; Ritux, rituximab; RT, radiation therapy; SCT, stem cell transplantation; SLL, small lymphocytic lymphoma; TBI, total body irradiation; TRM, treatment-related mortality; Tx, treatment, VADE,
vincristine/adriamycin/dexamethasone/etoposide; VIM, etoposide/ifosfamide/methotrexate; VP-16, etoposide, WF, working formulation.
*Quality and strength of evidence definitions are listed in Table 1.
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Appendix C. Noncomparative Studies of Autologous SCT for DLBCL
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
UPDATE DATA (POST-2000 STUDIES)
MULTIPLE OR TANDEM AUTOLOGOUS SCTAS FIRST-LINE THERAPY FOR DLBCL
[44] Debulking Diagnoses [4 y (Not stated)]
Tarella 2007 3 APO de novo HR DLBCL 100%
2+ HDS + Multiple Auto PBSCT Hist. Subtypes Completed Tx 83%
Cy + Ritux DLBCL 79%
1999-2004 Y PMBL 10% Overall CR 80.4%
GITIL Multicenter (6) 6 Ara-C Transformed 8%
Prospective Y T cell rich 3% (ITT)
n 5 112 in vivo purged Auto PBSCT
Y aaIPI Early TRM 4.5%
Med Age (range) 48 y (18-66) Ritux on days +8 and +18 2 66%
Y 3 34% 4-year EFS 73%
VP-16 + Cisplatin CI 64%-81%
Y Bulky disease 52%
in vivo purged Auto PBSCT 4-year OS 76%
Y BM Involvement 31% CI 68%-85%
Mito + Mel
Y Risk Factors
in vivo purged Auto PBSCT Stage $III 81%
+ Ritux on days +30 and +37 LDH >normal 75%
± $2 Ex-nodal sites 30%
RT post-PBSCT for bulky dis. PS $2 68%
[45] 4 MegaCHOEP Diagnoses [4.6 y (Not stated)]
Glass 2006 (After courses 1 and 3 de novo Aggress NHL 100%
Cy + VP-16 doses escalated)
2+ Hist. Subtypes Completed Tx 81.8%
SC Mobilization DLBCL 73%
1999-2004 GF after courses 1 and 2 T cell 13% Overall CR 70%
Prospective Multicenter (31) B cell unspecified 7%
Enrolled n 5 124 Auto PBSCT after courses 2, 3, and 4 FL 4% (ITT)
Included n 5 112 MC 2%
DLBCL n 5 77 (73%) (Stratified) Burkitt 1% Overall TRM 4.5%
Med Age (range) 44 y (18-60) Bulky Disease 64% DLBCL Only
5-year FFS 61.8%
BM Involvement 70% CI 50.4%-73.2%
B Symptoms 65% 5-year OS 62.6%
CI 50.7%-74.5%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Risk Factors
aaIPI $3 20%
Stage $III 61%
LDH >normal 100%
$2 Ex-nodal sites 33%
PS $2 28%
[46] CEOP + GF (Cycles 1 & 2) Diagnoses [2.5 y (1.8-5.3 y)]
Coso 2006 de novo HR NHL 100%
2x CEOP + VP-16 + Cisplatin + GF
2+ (Cycles 3 & 4) Hist. Subtypes Completed Tx 83%
DLBCL 94%
1999-2002 Auto PBSCT after cycles 3 & 4 Anaplastic 6% Overall CR 72%
Prospective R-ISC 98 Trial
Enrolled n 5 36 4 Ritux Risk Factors (ITT)
Received Tandem Auto SCT n 5 30 aaIPI $3 36%
Received Ritux Post-Auto n 5 24 Stage $III 89% 5-year EFS 63%
LDH >normal 92% CI 50%-81%
Med Age (range) 42 y (20-59) $2 Ex-nodal sites (n 5 25) 28%
PS $2 42% 5-year OS 65%
CI 52%-84%
Rec’d Ritux
(n 5 24)
82%
5-year EFS CI 72%-100%
86%
5-year OS CI 68%-99%
[47] Induction (Tandem Pts Only) [3.5 y (Not stated)]
Haioun 2001 4 ACVBP + GF
Diagnoses
2+ SC Mobilization de novo HR NHL 100% (All 28 Pts)
Cy + VP-16 + GF
1995-1997 Hist. Subtypes Completed Tx 86%
Prospective Multicenter (4) 1st Auto PBSCT DLBCL 73%
Enrolled n 5 36 HDT: BCV-Mito T cell 27% Overall CR 61%
Eligible for Auto SCT n 5 28 followed by 1st reinfusion
Tandem Auto SCT n 5 24 Bulky Disease 75% Overall TRM 11%
2nd Auto PBSCT
Med Age (range) 44 y (16-60) HDT: BCM BM Involvement 29% Overall Relapse 32%
Followed by 2nd reinfusion
(med 62 days after 1st) Risk Factors
(Continued )
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
7
:2
0
-4
7
,
2
0
1
1
4
7
.e
1
2
T
h
e
R
o
le
o
f
C
yto
to
x
ic
T
h
e
ra
p
y
w
ith
H
e
m
a
to
p
o
ie
tic
S
C
T
in
th
e
T
re
a
tm
e
n
t
o
f
D
L
B
C
L
Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Tandem Only
(This is the updated and ± GF aaIPI $3 100% (n 5 24)
published version of the Stage $III 100% 3-year OS
Haioun et al. [48] LDH >normal 100% 67%
abstract discussed in the $2 Ex-nodal sites 71% CI 43%-79%
original DLBCL EBR) PS $2 54%
MULTICENTER STUDIES OF AUTOLOGOUS SCTAS FIRST-LINE THERAPY FOR DLBCL
[49] Diagnoses [6.5 y (.5-12.1 y)]
Mounier 2004 Induction de novo Aggress NHL 100%
4 ACVB
2++ Hist. Subtypes (All Pts)
HDT DLBCL 55%
1987-1993 BEAM or CBV T cell 16% Overall CR 61%
GELA LNH-87 and LNH-93 trials Burkitt 15% CRu 39%
Retrospective analysis Auto SCT (61% BM) Immunoblastic 3%
Total n 5 1734 ± RT FL 2% TRM 1%
Subgroup analyzed n 5 330 Unclassified 9%
DLBCL n 5 172 (55%) (Stratified) Relapse 32%
Bulky Disease 62%
Med Age (range) 39 y (16-60) 5-year DFS 67 ± 5%
Risk Factors
aaIPI $3 66% 5-year OS 75 ± 5%
Stage $III 75%
LDH >normal 72% DLBCL Only
$2 Ex-nodal sites 43% 5-year DFS 68 ± 6%
PS $2 23%
5-year OS 76 ± 5%
[50] Induction: 4 MegaChop + GF Diagnoses [2.8 y (Not stated)]
Arranz 2008 de novo Aggress NHL 100%
HDT: BEAM
2++ Hist. Subtypes Completed Tx 81%
Auto SCT (94% PBSC) DLBCL 86%
2001-2005 PMBL 9% Overall CR 85%
GEL/TAMO Multicenter FL Grade 3 5%
Prospective (ITT)
Enrolled n 5 86 Bulky Disease 42%
TRM 7%
Med Age (range) 53 y (18-68) BM Involvement 29%
5-year PFS 67%
B Symptoms 58% CI 55%-79%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Risk Factors 5-year OS 74%
IPI $3 79% CI 59%-87%
Stage $III 88%
LDH >normal 82%
PS $2 48%
[51] Induction Diagnoses [2.3 y (0-14 y)]
Caballero 2003 CHOP (51%) or other DLBCL 100%
2+ HDT Status at SCT TRM 11%
BEAM (39%) or BEAC (33%) CR1 or PR1 53%
1994-1999 or CBV (10%) or other chemo (5%) >CR1 or PR1 35% Relapse 11%
GEL/TAMO Multicenter or Cy + TBI (12%) Refractory 12%
Retrospective analysis ± GF 5-year DFS 43%
Analyzed d n 5 452 Bulky Disease 53%
Auto SCT (52% PBSC) 5-year OS 53%
Med Age (range) 42 y (15-73) BM Involvement 22%
Med Dx to SCT (range) Prior Chemo Reg $2 35%
.92 y (0.1-16.6 y)
Risk Factors
aaIPI $2 61%
Stage $III 73%
LDH >normal 62%
$2 Ex-nodal sites 28%
PS $2 41%
SINGLE CENTER STUDIES OF AUTO SCTAS FIRST-LINE THERAPY FOR DLBCL
[52] HDS Diagnoses [3.5 y (0.75-8.3 y)]
Papajik 2008 PACEBO ± Ritux de novo DLBCL 100%
Y
2+ IVAM Status at SCT Overall CR 62%
Y CR 35%
1999-2006 HAM PR 65% TRM 0%
Single Center
Retrospective HDT: BEAM Bulky Disease 55% Relapse 7%
n 5 55
Auto PBSCT BM Involvement 18% 5-year EFS 76%
Med Age (range) 41 y (19-62) ± RT CI 63%-89%
Risk Factors
Age $40 y 53% 5-year OS 85%
IPI $3 36% CI 73%-97%
(Continued )
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
7
:2
0
-4
7
,
2
0
1
1
4
7
.e
1
4
T
h
e
R
o
le
o
f
C
yto
to
x
ic
T
h
e
ra
p
y
w
ith
H
e
m
a
to
p
o
ie
tic
S
C
T
in
th
e
T
re
a
tm
e
n
t
o
f
D
L
B
C
L
Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Stage $III 78%
$2 Ex-nodal sites 58%
LDH >normal 60%
[53] Induction Diagnoses [4.1 y (1.2-6.1 y)]
Stewart 2006 1 CHOP de novo Aggress NHL 100%
Y
2+ 1x DICEP + GF Hist. Subtypes Completed Tx 93%
DLBCL 94%
1998-2004 HDT: BEAM Burkitt 2% NRM 2%
Single Center FL Grade 3 2%
Prospective Auto PBSCT T cell 2% 4-year EFS 72%
n 5 55 ± RT CI 60%-84%
Bulky Disease 62%
Med Age (range) 44 y (20-63) 4-year OS 79%
BM Involvement 29% CI 69%-90%
Risk Factors
aaIPI $3 35%
Stage $III 91%
LDH >normal 86%
$2 Ex-nodal sites 66%
PS $2 78%
[54] Induction Diagnoses [2.9 y (1.3-9.3 y)]
Vranovsky 2008 MACOP-B (10 weeks) de novo Aggress NHL 100%
2+ Consolidation Hist. Subtypes Completed Tx 93%
2x DHAP or mini-BEAM DLBCL 68%
1997-2005 T cell 15% 100-day TRM 8.5%
Single Center HDT: BEM or CBV Anaplastic 11%
Retrospective MC 6% 5-year PFS 66%
n 5 47 Auto PBSCT + GF CI 49%-81%
B Symptoms 81%
Med Age (range) 44 y (20-60) 5-year OS 59%
Bulky Disease 23% CI 42%-76%
BM Involvement 45%
Risk Factors
aaIPI $3 47%
Stage $III 98%
LDH > normal 89%
PS $2 45%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
[55] Induction Diagnoses [10.2 y (7.2-12.3 y)]
Bertz 2004 6 or 12 VACOP-B de novo HG BCL 100%
2+ SC Mobilization Hist. Subtypes Completed Tx 100%
VP-16 + Ifo + Cisplatin + Epirubicin + GF DLBCL 61%
1992-1997 PMBL 21% Overall CR 94%
Single Center B Immunoblastic 12%
Retrospective HDT Unclassified B cell 6% TRM 0%
n 5 33 BEAM or Bu + Cy
Bulky Disease 30% 10-y Relapse 16%
Med Age (range) 43 y (19-56) Auto SCT + GF ± RT
Risk Factors 10-year DFS 76%
AaIPI $3 67% CI 67%-86%
Stage $III 54%
LDH >normal 85% 10-year OS 79%
$2 Ex-nodal sites 27% CI 68%-89%
PS $2 52%
PURGED AUTOLOGOUS SCTAFTER PRIMARY INDUCTION FAILURE
[56] Induction Diagnoses [7.3 y (0.1-16.3 y)]
Benjamin 2009 CHOP (70%), R-CHOP (14%), de novo DLBCL 100%
or other (16%)
2+ Status at SCT Overall CR 77%
PBSC Mobilization PR 51%
1988-2002 Cy or VP-16 SD 49% NRM 12%
Single Center
Retrospective HDT Med Chemo Cycles (range) 6 (2-12) 5-year EFS 59%
n 5 43 Carmustine + VP-16 + Cy (60%) CI 42%-74%
or TBI + VP-16 + Cy (35%) Pre-SCT RT 23%
Med Age (range) 43 y (19-64) or Lomustine + Cy + VP-16 (5%) 5-year OS 69%
B Symptoms 60% CI 55%-83%
Med Dx to SCT (range) B-cell purged Auto SCT (86% PBSCT) Secondary
0.73 y (0.2 -1.3 y) ± RT Bulky Disease 40% MDS 5%
BM Involvement 23%
Risk Factors
aaIPI $2 33%
Stage $III 72%
$2 Ex-nodal sites 26%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
INTENSIFIED OR HIGH DOSE SEQUENTIALTHERAPY + AUTO SCTAS SALVAGE THERAPY FOR DLBCL
[57] First-line Tx Diagnoses [2 y (0.5-14.5 y)]
Cortelazzo 2001 CHOP or MACOP-B/VACOP-B Aggressive NHL 100%
or Chlorambucil or Flu Relapsed 63%
2++ Refractory 37% Overall CR 90%
Debulking
1985-1999 2 APO Hist. Subtypes TRM 4%
Retrospective Multicenter (9) DLBCL 74%
n 5 103 HDS T cell 26% 3-year EFS 44%
HD Cy CI 34%-54%
Med Age (range) 43 y (16-65) Y Med Chemo Cycles (range) 7 (3-17)
HD MTX + Vincristine 3-year OS 47%
Y B Symptoms 15% CI 36%-59%
HD VP-16 Secondary
+ GF Bulky Disease 31% Neoplasias 4%
HDT BM Involvement 20%
HD Mito + Mel or
BEAM or Thiotepa + L-PAM or Risk Factors
HD Mel + TBI IPI $2 37%
Stage $III 65%
Auto (89% PBSCT) ± GF LDH >normal 27%
± RT $2 Ex-nodal sites 16%
PS $2 19%
[58] SC Mobilization Diagnoses [4 y (Not stated)]
Robertson 2005 GF ± Cy Aggressive NHL 100%
2++ HDT Hist. Subtypes NRM 6%
Augmented HD CBV DLBCL 73%
1993-2001 Burkitt 7.5% 3-year PFS 36% ± 6%
Prospective, Single Center Unpurged Auto PBSCT Anaplastic 6%
n 5 67 + GF MC 4.5% 3-year OS 46% ± 8%
T Cell 4.5%
Med Age at SCT (range) 52 y (23-72) No adjuvant Ritux Other 4.5% Secondary
Neoplasias 0%
Hist. Transformed 16%
Status at SCT
Refractory 42%
Early relapse 27%
Late relapse 28%
Other 3%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Prior Chemo Reg >2 18%
Bulky Disease 3%
LDH >normal 57%
[59] Debulking Diagnoses [2.1 y (0.1-6.3 y)]
Josting 2005 2 DHAP + GF Aggressive NHL 100%
Refractory 40%
2+ HDS Relapsed 60% Overall CR 43%
HD Cy + GF
Study dates not stated Y Hist. Subtypes TRM 0%
Prospective, Multicenter (13) HD MTX + Vincristine DLBCL 73%
n 5 57 Y T Cell 19% 2-year FFS 25%
HD VP-16 + GF MC 2%
Med Age at SCT (range) 43 y (24-65) Other 6% 2-year OS 47%
HDT: BEAM
Hist. Transformed DLBC 19%
Auto PBSCT + GF
± RT Prior RT 28%
B Symptoms at Relapse 34%
Stage $III 54%
AUTOLOGOUS SCT WITH RITUXIMAB AS SALVAGE THERAPY FOR DLBCL
[60] 1 Ritux 1 day prior Diagnoses [5.5 y (1.4-12.2 y)]
Alousi 2008 to unspecified chemomobilization DLBCL 100%
2+ Auto PBSCT Hist. Subtypes 6-year TRM 6%
+ Ritux on days 1 and 8 after PBSCT DLBCL 78% CI 3%-11%
1995-2005 DLBCL-transformed FL 22%
Retrospective, Single Center 5-year PFS 48%
n 5 174 Status at SCT CI 40%-56%
CR 12%
Med Age (range) 47 y (16-75) CRu 38% 5-year OS 62%
PR 50% CI 54%-69%
Prior Chemo Reg >2 30%
Ritux pre/post PBSCT 37%
Risk Factors
Age $60 51%
IPI $1 30%
LDH >Normal 21%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
[61] SC Mobilization Diagnoses [2.5 y (Not stated)]
Horwitz 2004 Cy + GF Aggressive NHL 100%
(ITT)
2+ HDT Hist. Subtypes
Carmustine + VP-16 + Cy DLBCL 71% NRM 3%
1998-2000 or TBI + VP-16 + Cy (8.5%) Other B cell 11%
Prospective, Single Center Transformed 9% 2-year EFS 83%
n 5 35 Purged (mAbs) Auto PBSCT ± GF MC 9% CI 70-95%
Y
Med Age at SCT (range) 51 y (28-70) Day 42 Ritux weekly x 4 Status at SCT 2-year OS 88%
Y CR1 20% CI 78%-99%
Day 180 Ritux weekly x 4 Refractory 29%
Relapsed 51% DLBCL Only
2-year EFS 81%
Med Chemo Reg (range) 2 (Not stated) CI 64%-98%
2-year OS 85%
CI 70%-100%
INVOLVED-FIELD RADIATION PRIOR TO HDT + AUTOLOGOUS SCTAS THERAPY FOR DLBCL
[62] First-Line Therapy Diagnoses [5 y (1.7-15.6 y)]
Hoppe 2008 CHOP (81%) or Dox-based (18%) DLBCL 100%
or Unknown (1%)
2+ ± RT (10%) Hist. Subtypes TRM 6%
DLBCL 87%
1990-2006 Pretransplant IFRT PMBL 13% Relapsed 41%
Retrospective, Single Center 30 Gy (54%) or
n 5 164 18 Gy IFRT + 12 Gy TBI (as part of Status at SCT 5-year PFS 53%
HDTregimen) (46%) Refractory 24%
Med Age (range) 46 y (17-73) Relapsed 59% 5-year OS 58%
HDT Transformed (DLBCL
BEAM (42%) at relapse) 8.5% Secondary
Ifo + VP-16 (22.5%) High risk (Stage IV bulky Neoplasias 7%
Cy + VP-16 (22.5%) or high IPI score) 8.5% MDS 2%
CBV (7%)
Other (6%) Med IFRT dose (range) 30 Gy (21-45)
(± 12 Gy TBI)
Med IFRT to SCT (range) 21 days (12-98)
Auto (85% PBSCT)
Bulky Disease 12%
BM Involvement 7%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Risk Factors
aaIPI $2 30%
Stage $III 49%
LDH > normal 49%
Ex-nodal sites involved 61%
PS $2 13%
MULTICENTER STUDIES OF AUTOLOGOUS SCTAS SALVAGE THERAPY FOR DLBCL
[63] HDT Diagnoses [3.7 y (0.1-10.3 y)]
Vose 2004 Chemotherapy only (32%) Aggress. Diffuse NHL 100%
TBI-based regimen (68%)
2++ Hist. Subtypes TRM 6%
Auto BMT (49%) DLBCL 60%
1989-1996 Auto PBSCT (41%) Diffuse mixed cell 20% 3-yr Rel/Prog 63%
ABMTR Multicenter (93) Auto with both BM and PBSC (10%) Immunoblastic 20% CI 58%-68%
Retrospective ± GF
n 5 429 Status at SCT 3-year PFS 31%
CR2 35% CI 27%-36%
Med Age at SCT (range) 49 y (5-71) Relapse 1 65%
3-year OS 44%
B Symptoms 35% CI 33%-55%
BM Involvement 14%
Risk Factors
Age $40 y 72%
Stage $III 62%
LDH >normal 31%
Ex-nodal sites involved 17%
Karnofsky PS <90% 34%
[64] HDT Diagnoses [3.4 y (2-8.6 y)]
Vose 2001 TBI + Other (27%) Aggress. Diffuse NHL 100%
BEAC (27%)
2+ CBV (19%) Hist. Subtypes Overall CR 44%
Other (27%) DLBCL 60%
1985-1995 Diffuse mixed cell 15% 100-Day NRM 39%
ABMTR Multicenter (48) Auto BMT (56%) Immunoblastic 25%
Retrospective Auto PBSCT (37%) 5-year PFS 31%
n 5 184 Auto with both BM + PBSC (7%) Status at SCT CI 24%-38%
± GF Sensitive 60%
Med Age at SCT (range) 42 y (9-69) ± RT Resistant 28% 5-year OS 37%
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Unknown 12% CI 30%-45%
B Symptoms 54%
BM Involvement 21%
Prior Chemo Reg $2 36%
Risk Factors
Stage $III 63%
LDH >normal 67%
Karnofsky PS <80% 14%
[65] First-line Tx Diagnoses [2.4 y (0.1-6.7 y)]
Rodriguez 2004 CHOP (59%) DLBCL 100%
Other (41%)
2+ Status at SCT Overall CR 54%
HDT PR 65%
1990-1999 BEAM (44%) Treatment failure 35% TRM 8%
GEL/TAMO Multicenter BEAC (28%)
Retrospective Cy + TBI (12%) B Symptoms 53% 5-year DFS 63%
n 5 114 CBV (10%) (for CR pts)
Other (6%) BM Involvement 19%
Med Age at SCT (range) 40 y (13-73) 5-year OS 43%
Auto BMT (30%) Bulky Disease 69%
Auto PBSCT (63%)
Auto with both BM + PBSC (7%) ± GF Prior Chemo Reg $2 56%
Risk Factors
aaIPI $2 73%
Stage $III 75%
LDH >normal 72%
Ex-nodal sites $2 31%
PS $2 53%
SINGLE-CENTER STUDIES OF AUTOLOGOUS SCTAS SALVAGE THERAPY FOR DLBCL
[66] First-line Tx Diagnoses [5 y (1-14.2 y)]
Lerner 2007 CHOP (61%) DLBCL 100%
Other anthracycline-based regimen (34%)
2++ Other (4%) Hist. Subtypes Overall CR 91%
DLBCL 66%
1984-2002 HDT Diffuse mixed cell 14% Pre 1993 TRM 19%
Retrospective, Single Center TBI-based regimen (74%) Immunoblastic 16%
(Continued )
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Analyzed n 5 80 Chemotherapy only (26%) Anaplastic 4% Post 1993 TRM 2%
Med Age at SCT (range) 47 y (19-68) Auto BMT (51%) Response to Salvage 5-year PFS 32%
Auto PBSCT (45%) CR 34% CI 22-42%
Auto with both BM + PBSC (4%) PR 66%
± GF 5-year OS 38%
B Symptoms 25% CI 27-50%
BM Involvement 10%
Risk Factors
Age > 60 y 15%
IPI $2 13%
Stage $III 48%
LDH >normal 72%
Ex-nodal sites $2 20%
PS $2 20%
[67] DLBCL Pts. Only Diagnoses [Minimum 10 months (Not stated)]
Sohn 2009 DLBCL 100%
HDT DLBCL Only
2++ BEAM (41%) Hist. Subtypes
BEAC (41%) DLBCL 70% Overall CR 61%
1993-2006 Bu + Cy + VP-16 ± Yttrium-90 (18%) T Cell 30%
Retrospective, Single Center 2-year EFS 40%
n 5 77 Auto SCT DLBCL Pts. Only CI 27%-53%
DLBCL n554 (70%) (Stratified)
Status at SCT 2-year OS 46%
DLBCL Pts. Only CR1 15% CI 33%-59%
Med Age at SCT (range) 48 y (15-68) PR1 24%
CR2 15%
PR2 29%
Refractory 17%
Timing of SCT
Front-line therapy 30%
First relapse 70%
Risk Factors
Age >60 y 15%
aaIPI $2 24%
IPI $3 17%
Stage $III 33%
LDH >normal 57%
Ex-nodal sites $2 13%
PS $2 6%
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
[68] Second-line Tx Diagnoses [4 y (0.67-8.2 y)]
Hamlin 2003 ICE ± RT DLBCL 100%
2+ HDT Status at SCT Completed Tx 68%
Chemotherapy only (57%) Relapsed 55%
1993-2000 TBI-based regimen (43%) Refractory 45% (ITT)
Retrospective, Single Center
n 5 150 Auto SCT BM Involvement 22% 4-year PFS 28%
Med Age at SCT (range) 49 y (16-68) Risk Factors 4-year OS 34%
Age $60 y 17%
aaIPI $2 60%
Stage $III 78%
LDH <normal 58%
Ex-nodal sites $2 44%
Karnofsky PS <80% 44%
[69] DLBCL Pts. Only Diagnoses [1.8 y (0.1-7.8 y)]
Kuruvilla 2008 Rel/Ref B-cell NHL 100%
Initial Chemotherapy
2+ CHOP or CHOP-like (89%) Hist. Subtypes DLBCL Only
Ritux + CHOP (10%) DLBCL 79%
1995-2004 ABVD (1%) PMBL 21% Completed Tx 50%
Retrospective, Single Center
n 5 180 Salvage Tx DLBCL Pts. Only TRM 1%
DLBCL n 5 143 (79%) (Stratified) DHAP, ESHAP, GDP, or mini-BEAM
+ GF Response to Salvage 2-year PFS 36%
DLBCL Pts. Only CR or CRu 12%
Med Age at SCT (range) 53 y (21-66) 2nd Line of Salvage Tx (34%) PR 36% 2-year OS 53%
SD 17%
HDT PD 35%
VP-16 + Mel + GF
Prior Radiation 23%
Auto BMT
± RT B Symptoms 13%
Bulky Disease 21%
Risk Factors
Age >60 y 15%
IPI $2 42%
Stage $III 49%
LDH >normal 59%
Ex-nodal sites $2 9%
PS $2 19%
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
[70] Salvage Tx Diagnoses [2.8 y (0.1-13.7 y)]
Song 2003 Cisplatin-based regimen or mini-BEAM Rel/Ref NHL 100%
2+ HDT Hist. Subtypes DLBCL Only
VP-16 + Mel ± TBI DLBCL 73%
1987-2001 T Cell 27% Completed Tx 50%
Retrospective, Single Center SC Source for DLBCL Pts. Only
n 5 133 Auto BMT (45%) DLBCL Pts. Only TRM 7%
DLBCL n 5 97 (73%) (Stratified) Auto PBSCT (41%)
Auto with both BM + PBSC (14%) Response to Salvage Relapsed 46%
DLBCL Pts. Only CR 37%
Med Age at SCT (range) 46 y (19-65) PR 57% 3-year EFS 42%
<PR 6% CI 32%-53%
Risk Factors 3-year OS 53%
Stage $III 42% CI 42%-64%
LDH >normal 12%
Ex-nodal disease 25%
[71] Diagnoses [6.3 y (Not stated)]
Kewalramani 2006 DLBCL HDT Rel/Ref NHL 100%
TBI-based regimen (56%)
2+ Chemotherapy only (44%) Hist. Subtypes DLBCL Only
DLBCL 78%
1993-2003 Auto SCT T Cell 22% 5-year PFS 34%
Retrospective, Single Center
n 5 110 DLBCL Pts. Only 5-year OS 39%
DLBCL n 5 86 (78%) (Stratified)
Response to Induction
DLBCL Pts. Only Refractory 30%
Med Age at SCT (range) 47 y (18-68) Relapse 70%
Response to Salvage
CR 41%
PR 59%
Risk Factors
aaIPI $3 54%
IPI $3 34%
[72] PBSC Mobilization Diagnoses [2.8 y (0.3-13.6 y)]
McCoy 2004 Cy + GF Relapsed NHL 100%
2+ HDT Hist. Subtypes Day-100 CR Rate 62%
Thiotepa + VP-16 DLBCL 76%
1987-2001 FL 9% NRM 8%
Retrospective, Single Center Auto SCT (BM or PBSC or both) Other Diffuse 7%
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
n 5 65 Anaplastic 5% 3-year EFS 32%
T Cell 3% CI 20%-45%
Med Age at SCT (range) 49 y (19-64)
Status at SCT 3-year OS 40%
CR1 5% CI 26%-53%
CR2 26%
PR (includes 12 PIF) 46%
<PR (includes 8 PIF) 23%
Med Chemo Reg (range) 2 (1-6)
Stage $III 65%
[73] CHOP or BEAC for induction Diagnoses [2.8 y (.3-13.6 y)]
Usui 2005 EPOCH for salvage Aggressive NHL 100%
2+ HDT Hist. Subtypes Day-100 CR Rate 62%
ACNU DLBCL 61%
1991-2001 FL 12% NRM 8%
Prospective, Single Center Auto PBSCT (61%) Other Diffuse 17%
n 5 56 Auto BMT (5%) Immunoblastic 4% 3-year EFS 32%
Auto with both BM + PBSC (34%) Lymphoblastic 4% CI 20%-45%
Med Age at SCT (range) 46 y (20-61) ± RT Burkitt 2%
3-year OS 40%
Status at SCT CI 26%-53%
CR1 16%
$CR2 18%
PR1 25%
$PR2 21%
No response 20%
Med PS (range) 1 (0-2)
[74] PBSC Mobilization Diagnoses [2.2 y (0.3-5 y)]
Smith 2009 VP-16 ± GF DLBCL 100%
2+ HDT Hist. Subtypes de novo DLBCL
Bu + VP-16 + Cy de novo DLBCL 55%
2003-2008 HT DLBCL (from FL) 45% 3-year RFS 59%
Retrospective, Single Center Auto PBSCT + GF
n 5 56 SCT as Front-line Tx 30% 3-year OS 59%
Med Age at SCT (range) 57 y (30-72) Prior Chemo Reg $3 34% HT DLBCL
Prior mAbs Tx 93% 3-year RFS 64%
Refractory at SCT 9% 3-year OS 63%
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
Bulky Disease 18%
Risk Factors
IPI $3 20%
LDH >Normal 63%
Karnofsky PS <80% 27%
[75] Salvage Tx: Not specified Diagnoses [2.8 y (0.3 – 13.6 y)]
Escalon 2009 Relapsed NHL 100%
PBSC Mobilization: GF
2+ Hist. Subtypes Day-100 NRM 9%
HDT DLBCL 65%
2000-2005 Bu + Cy FL 19% DLBCL Only
Retrospective, Single Center MC 9%
n 5 43 Auto PBSCT T Cell 7% 3-year EFS 35%
DLBCL n 5 28 (65%) (Stratified) + GF CI 18%-53%
Prior Chemo Reg >2 40%
Med Age at SCT (range) 50 y (20-68) 3-year PFS 41%
Status at SCT CI 21%-59%
CR 58.5%
CRu 2.5% 3-year OS 34%
PR 30% CI 17%-53%
SD 9%
Risk Factors
Age >60 21%
Stage $3 69%
[76] HDT Diagnoses [3.5 y (0.8-9.2 y)]
Mey 2007 Mega-CHOEP or BEAM or CEI DLBCL 100%
or CEIAP or IC
2+ Status at SCT TRM 12%
Auto PBSCT ± GF CR 8%
1996-2004 PR 60% 3-year OS 48%
Retrospective, Single Center SD 16%
n 5 25 PD 16%
Med Age at SCT (range) 43 y (18-69) BM Involvement 12%
Bulky Disesase 40%
Prior Chemo Reg $2 48%
Risk Factors
Age >50 y 40%
IPI $3 52%
Stage $III 56%
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Appendix C. (Continued )
Study Design Patient Outcomes
(Ref #), Qual. &
Strength of Evidence,*
and Patient Population Protocol Disease and Transplant Characteristics Follow-Up [Med (range)] & Patient Outcomes
LDH >normal 92%
Ex-nodal sites $2 60%
PS $2 4%
[77] PBSC Mobilization Diagnoses [7.6 y (1.9-12.3 y)]
Waheed 2004 GF ± Cy + VP-16 NHL 63%
Hodgkin Disease 37%
22 HDT Overall TRM 4%
Thiotepa + Mito + Carboplatin NHL Hist. Subtypes
1990-2001 DLBCL 86% Overall 5-y PFS 43%
Retrospective, Single Center Auto BMT (18%) T Cell 5%
n 5 100 Auto PBSCT (50% FL Grade 3 3% NHL Only
NHL n 5 63 (63%) (Stratified) Auto with both BM + PBSC (32%) MC 3%
DLBCL (86% of NHL) Lymphoblastic 1.5% Median OS 8.9 years
Anaplastic 1.5%
Med Age at SCT (range) 44 y (21-72)
Med Serum LDH (range) 181 (86-667)
B Symptoms 29%
Prior RT 42%
Prior Chemo Reg $2 90%
Risk Factors
Stage $III 69%
PS $1 45%
aaIPI indicates age-adjusted International Prognostic Index; ABMTR, Autologous Blood and Marrow Transplant Registry; ACNU, nimustine/etoposide/carboplatin/cyclophosphamide; ACVB, doxorubicin/mitoxan-
trone/cyclophosphamide; ACVPB, doxorubicin/cyclophosphamide/vindesine/bleomycin/methylprednisolone; APO, doxorubicin/vincristine/prednisone; Ara-C, cytarabine; Auto, autologous; BCL, B cell lymphoma;
BCM, busulfan/carboplatin/melphalan; BCV-Mito, carmustine/cyclophosphamide/etoposide/mitoxantrone; BEAC, bleomycin/etoposide/doxorubicin/cyclophosphamide; BEAM, carmustine/etoposide/cytarabine/
melphalan; BEM, carmustine/etoposide/melphalan; BM(T), bone marrow (transplantation); Bu, busulfan; CBV, cyclophosphamide/carmustine/etoposide; CEI, carboplatin/etoposide/ifosfamide; CEIAP, carboplatin/
etoposide/ifosfamide/adriamycin/dexamethasone; CEOP, cyclophosphamide/epirubicin/vincristine/prednisone; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CI, 95% confidence interval; CR,
complete remission; CRu, unconfirmed complete remission; Cy, cyclosphosphamide; DHAP, dexamethasone/cytarabine/cisplatin; DICEP, dose-intensive cyclophosphamide/etoposide/cisplatin; DLBCL, diffuse large
B cell lymphoma; Dx, diagnosis; EFS, event-free survival; EPOCH, etoposide/prednisone/vincristine/cyclophosphamide/doxorubicin; ESHAP, etoposide/cisplatin/methylprednisolone/cytarabine; FFS, failure-free survival;
FL, follicular lymphoma; Flu, fludarabine; GDP, gemcitabine/dexamethasone/cisplatin; GEL/TAMO, Spanish Group for Lymphoma and Autologous Transplantation; GF, growth factor; GITIL, Gruppo Italiano Terapie
Innovative nei Linfomi; HAM, cytarabine/mitoxantrone; HDS, high-dose sequential therapy; HDT, high-dose therapy; HG, high grade; HLA, human leukocyte antigen; HR, high risk; IC, thiotepa/busulfan/cyclophospha-
mide; Ifo, ifosphamide; IFRT, involved-field radiotherapy; IPI, International Prognostic Index; IVAM, ifosfamide/etoposide/cytarabine/methotrexate; LDH, lactate dehydrogenase; MACOP-B, methotrexate/doxorubicin/
cyclophosphamide/vincristine/prednisone/bleomycin; MC, mantle cell; MegaCHOEP, cyclophosphamide/adriamycin/vincristine/etoposide/prednisone; Mel, melphalan; Mito, mitoxanthrone; NRM, nonrelapsemortality;
PACEBO, prednisone/doxorubicin/cyclophosphamide/etoposide/bleomycin/vincristine; PBSC(T), peripheral blood stem cell (transplantation); PFS, progression-free survival; PMBL, primary mediastinal large B cell
lymphoma; PR, partial remission; PS, performance status; ritux, Rituximab; OS, overall survival; R-ISC, ritux + intensive sequential chemotherapy; RT, radiation therapy; SCT, stem cell transplantation; SD, stable disease;
SFGM-TC, Socie´te´ Franc¸aise de Greffe de Moelle et de The´rapie Cellulaire; TBI, total-body irradiation; TRM, treatment-related mortality; Tx, treatment, VACOP-B, doxorubicin/cyclophosphamide/vincristine/
bleomycin; VP-16, etoposide.
*Quality and strength of evidence definitions are listed in Table 1.
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Appendix D. Noncomparative Studies of Allogeneic SCT for DLBCL
Study Design Patient Outcomes
[Ref #], Qual. &
Strength of Evidence,*
and Patient Population Protocol
Disease and
Transplant Characteristics
Follow-Up [Med (Range)] &
Patient Outcomes
UPDATE DATA (POST-2000 STUDIES)
MYELOABLATIVE ALLOGENEIC SCT FOR DLBCL
[78] Prior Auto SCT 0% Diagnoses [5 y (1.1-11.4 y)]
Doocey 2005 Rel/Ref Aggressive NHL 100%
Conditioning
2++ Cy + TBI 82% Hist. Subtypes 1-year TRM 25%
Cy + TBI + VP-16 14% DLBCL 52% CI 13%-39%
1987-2003 Bu + Cy 4% Transformed B cell 37%
Single Center T cell lymphoma 11% 5-year EFS 43%
Retrospective Donors CI 27%-58%
n 5 44 MRD 75% Response to Initial Chemo
MUD 21% CR 62% 5-year OS 48%
Med Age (range) 40 y (15-56) MMUD 4% PR 20% CI 32%-63%
Stable/Progressive Disease 18%
Med Chemo Regimens (range) 2 (1-3) BM (89%) or PB 5-year Relapse 32%
Allo SCT Disease Status at SCT CI 18%-47%
Med Relapse to SCT (range) 0.33 y (0.1-1.1) PR1 20%
Relapse—sensitive 60%
Relapse—resistant 11%
PIF 9%
BM Involvement 32%
Risk Factors
Transformed from FL 37%
Stage $III 80%
REDUCED INTENSITY CONDITIONING ALLOGENEIC SCT FOR DLBCL
[79] Prior Auto SCT 79% Diagnoses [4.1 y (0.8-8 y)]
Sirvent 2009 Ref/Rel DLBCL 100%
Conditioning
2++ Flu-based chemo 74% Disease Status at SCT 1-year NRM 23%
Flu + 2 Gy TBI 25% CR 47% CI 12%-34%
1998-2007 Cy + 6 Gy TBI 1% PR 34%
SFGM-TC Multictr (23) (No Ritux) Stable or PD 17% 2-year PFS 44%
Retrospective CI 32%-56%
n 5 68 Donors >2 Prior Chemo Reg 37%
MRD 84% 2-year OS 49%
Med Age (range) 48 y (17-66) MUD 8% Risk Factors CI 37% -61%
MMUD 2% Transformed from FL 21%
Med Dx to SCT (range) 1.8 y (0.4- 10.4 y) IPI $2 47% 2-year Relapse 41%
T cell depletion 56% CI 28 - 54%
(ATG or mAbs)
PB (82%), BM, or
cord Allo SCT
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Appendix D. (Continued )
Study Design Patient Outcomes
[Ref #], Qual. &
Strength of Evidence,*
and Patient Population Protocol
Disease and
Transplant Characteristics
Follow-Up [Med (Range)] &
Patient Outcomes
[80] Aggress/Highly Aggress Only Diagnoses [2 y (.3 – 3.7 y)]
Kusumi 2005 Indolent NHL 40%
Prior Auto SCT 45% Aggressive NHL 52%
2+ Highly Aggressive NHL 8% Overall
Prior RT 37% 3-year TRM 25.2%
1999-2002 Aggessive/Highly Aggress
Multictr (32) Conditioning Chemosensitivity at SCT Aggress. Only
Retrospective Flu-based chemo 79% Sensitive 57% 3-year OS 48%
Total n 5 112 Flu + 2 Gy TBI 4% Resistant 43% CI 35%-61%
Aggressive/Highly Aggress. n 5 67 (60%) 2 Gy TBI 8%
DLBCL n 5 31 (28% of total; 46% A/HA) Other 9% Risk Factors DLBCL Only
(OS Stratified) Transformed from FL 6% 3-year OS 31%
Donors LDH > normal 51% CI 13%-49%
Aggressive/Highly Aggressive Only MRD (sibling) 81% PS $2 21%
Med Age (range) 50 y (22-72) MMRD 8%
MUD 11%
Med Dx to SCT (range) 1.6 y (0.3-12.1 y)
T cell depletion 0%
Med Chemo Regimens (range) 4 (1-14)
PB (80%) , BM, or
cord Allo SCT
[81] Prior Auto SCT 71% Diagnoses [4.3 y (1.5–7.4 y)]
Thomson 2009 de novo DLBCL 62%
Prior Ritux 56% DLBCL, transformed FL 38%
2+ 4year NRM 32%
Conditioning Chemosensitivity at SCT
1998-2006 Flu + Mel + Sensitive 83% 4-year PFS 48%
Multictr (8) Alemtuzumab 100% Resistant 17%
Retrospective 4-year OS 47%
n 5 48 Donors
MRD 60% 4-year Relapse 33%
Med Age (range) 46 y (23-64) MMRD 2%
MUD 21%
Med Dx to SCT (range) 4.2 y (0.6-17.3 y) MMUD 17%
Med Chemo Regimens (range) 5 (2-7) PB (83%) or BM
Allogeneic SCT
[82] Prior Auto SCT 75% Diagnoses [3.8 y (0.5-5.8 y)]
Rezvani 2008 Relapsed DLBCL (n 5 31) 97%
Conditioning Burkitt (n 5 1) 3%
2+ Flu + 2 Gy TBI 91% 3-year NRM 25%
2 Gy TBI 9% Disease Status at SCT
1996-2006 CR 44% 3-year PFS 35%
(Continued )
4
7
.e
2
9
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
7
:2
0
-4
7
,
2
0
1
1
D
.
M
.
O
lia
n
sky
e
t
a
l.
Appendix D. (Continued )
Study Design Patient Outcomes
[Ref #], Qual. &
Strength of Evidence,*
and Patient Population Protocol
Disease and
Transplant Characteristics
Follow-Up [Med (Range)] &
Patient Outcomes
Multictr (11) Donors PR 28%
Prospective MRD 66% Refractory 28% 3-year OS 45%
n 5 32 MUD 25%
MMUD 9% Chemosensitivity at SCT 3-year Relapse 41%
Med Age (range) 52 y (18-67) Sensitive 72%
PB (97%) or BM Resistant 28%
Med Dx to SCT (range) 3.4 y (0.6–7.9 y) Allogeneic SCT
BM Involvement at SCT 6%
Med Chemo Regs (range) 4 (2-7)
Allo indicates allogeneic; ATG, antithymocyte globulin; Auto; autologous; Bu, busulfan; CBV, cyclophosphamide/carmustine/etoposide; CI, 95% confidence interval; CR, complete remission; Cy, cyclosphosphamide;
DLBCL, diffuse large B cell lymphoma; Dx, diagnosis; EFS, event-free survival; HLA, human leukocyte antigen; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MRD, matched-related donor; MMRD,
mismatched related donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; NRM, nonrelapse mortality; PFS, progression-free survival; PS, performance status; Ritux, rituximab; OS, overall
survival; RT, radiation therapy; SFGM-TC, Socie´te´ Franc¸aise de Greffe de Moelle et de The´rapie Cellulaire; SCT, stem cell transplantation; TBI, total-body irradiation; TRM, treatment-related mortality; Tx, treatment.
*Quality and strength of evidence definitions are listed in Table 1.
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